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Abstract 
More and more people suffer from lifestyle diseases, such as cardiovascular diseases, 
diabetes and obesity. All of these diseases are in some way related to metabolism. Thousands 
of proteins and factors are involved in metabolism, making the pathways and interactions 
extremely complex. However, underlying it all are the genes that are encoding the proteins 
involved. Liver X Receptors (LXRs) are transcription factors in the nuclear receptor family. 
The LXRs are sensors in the cell and are activated by binding metabolites from cholesterol, 
glucose and fatty acid metabolism, before binding a huge variety of genes encoding proteins 
involved in lipid homeostasis, thus regulating pathways and interactions. Two isoforms of 
LXR have been identified, the LXRα and LXRβ. Animal and cell studies have shown that 
manipulation of LXR expression has an effect on the expected diseases such as 
atherosclerosis, diabetes, inflammation and obesity, but also Alzheimer’s disease and several 
types of cancer. Most of the ligands identified for LXRs are oxysterols, making LXRs ideal 
pharmaceutical targets for drugs against metabolic maladies. For structure-guided drug 
design it is important to obtain the structures of the LXR ligand-binding domains (LBD) with 
a ligand bound. The LBDs of the LXRs have been purified and crystallized by several 
groups, but no structures have been solved with both of the isoforms bound to the same 
endogenous ligand. The aim of this Master’s project was to express, purify and crystallize the 
LXRs ligand binding domains alone and in complex with the same endogenous and synthetic 
ligands, to be ready for structural studies by X-ray crystallography. The project was expected 
to be straightforward, however this was not the case as several problems arose during the 
expression, purification and crystallization. The original construct yielded little or no soluble 
protein after harvest. We tried out different varying the conditions during expression, had a 
ligand present in all solutions and transformed the constructs into cold-adapted cells, but it 
yielded little to no soluble protein. The proteins were expressed in huge amounts, but in the 
form of inclusion bodies. We tried to purify the aggregated protein and refold the proteis in 
vitro, but the proteins aggregated when concentrated to a medium concentration. The small 
soluble fraction of proteins was purified and used for cleavage tests with enterokinase to 
cleave off the purification tag. Enterokinase turned out to be highly unspecific making the 
cleavage of the tag difficult. Crystallization trials were done with the tag still on, but did not 
yield any crystals. So we decided to clone the genes into a new vector, encoding periplasmic 
expression. Although the ultimate goal of the project never was reached, the road towards it 
has been highly educational.  
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Sammendrag 
Stadig flere lider av livsstilssykdommer som forkalkning av blodårene, diabetes og fedme. 
Disse lidelsene fører ofte med seg de to hovedårsakene for dødsfall blant menn og kvinner, 
nemlig hjerte- og karsykdommer, og kreft. Alle disse lidelsene og de dødelige sykdommene 
som følger med dem, kan før eller siden relateres til metabolisme, hvor tusenvis av proteiner 
og faktorer er involvert. Syklusene og interaksjonene innenfor metabolismen kan være svært 
komplekse, men bakom er genene som styrer alt. Lever X Reseptorer (LXR) er 
transkripsjonsfaktorer innenfor kjernereseptorfamilien. To isoformer av LXR har blitt 
identifisert, LXRα og LXRβ, med 78% likhet i proteinsekvensene i deres to ligand-
bindingsdomener. Dyrestudier og in vivo studier har vist at manipulering av LXR ekspresjon 
har en effekt på de forventede sykdommene som aterosklerose, diabetes, inflammasjon, 
fedme, og overraskende nok også Alzheimers sykdom og visse typer kreft. De fleste ligander 
identifisert for LXR er endogene oksysteroler, noe som gjør LXR til ideelle farmasøytiske 
mål for medisiner mot metabolisme relaterte sykdommer. For strukturbasert “drug design” er 
det viktig å oppnå strukturer av de ligand-bindene domenene (LBD) i LXR med ligand. 
LBDene har blitt produsert, renset og krystallisert av flere grupper, men ingen strukturer av 
LXR LBD er løst der isoformene er bundet til samme endogene ligand. Målet med dette 
masterprosjektet var å rekombinant produsere, rense og krystallisere LXR LBD i kompleks 
med samme endogene og syntetiske ligander. Det var forventet at prosjektet skulle være 
ukomplisert, men det viste seg å ikke være tilfellet. Under produksjon av proteinene oppsto 
det mange problemer. De originale konstruktene gav lite eller ikke noe løselig protein under 
produksjon, men store mengder av protein i uløselige inklusjonslegemer. Vi forsøkte å 
variere kondisjonene og ha en ligand tilstedeværende i alle løsninger under ekspresjon, og 
transformere konstruktene inn i kuldetilpassede celler, men alle forsøk gav de samme 
resultatene med uløselig protein. Vi forsøkte dermed å rense protein fra inklusjonlegemene 
og folde proteinene in vitro. Dette resulterte i ustabile proteiner som ble utfelt ved 
konsentrering. Det proteinet renset fra den lille løselige fraksjonen ble brukt til 
krystalliseringsforsøk. Dette gav ingen krystaller, antageligvis på grunn av rensetag’en som 
forsatt satt på proteinet. Rensetag’en viste seg å være vanskelig å få av ettersom enterokinase 
er svært uspesifikk. Genene for LXR LBD ble klonet inn i en annen vektor som koder for 
periplasmisk ekspresjon.  	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List of Abbreviations  
 
____________________________________________________________________________________ 
AE      ArcticExpress 
Amp      ampicillin 
Bis-Tris (2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-1,3-
propanediol 
bp      base pair 
BSA      bovine serum albumin 
CV      column volume 
CIP      calf-intestinal alkaline phosphatase 
DNA      deoxyribonucleic acid 
dNTP      deoxyribonucleoside triphosphate 
dsDNA/ds     double-stranded DNA/double stranded 
DTT      dithiothreitol 
EDTA      ethylenediaminotetraacetic acid 
EKMax™     EnterokinaseMax™ (Invitrogen) 
ESRF      European Synchrotron Radiation Facility 
FD      FastDigest 
FPLC      fast performance liquid chromatography 
HEPES     N-2-hydroxyethylpiperazine-N’2-ethanesulfonic acid 
IPTG      isopropyl β-D-1-thiogalactopyranoside 
kbp      kilo base pairs 
LB      lysogeny broth 
LBD      ligand binding domain 
LMP      low melting point 
LXR      Liver X nuclear Receptor 
AU      absorption units 
MES      2-(N-morpholino)ethanesulfonic acid 
MQ-H2O     Milli-Q filtered and ion-exchanged water 
MW      molecular weight 
MWCO     molecular weight cut off 
NEB      New England Biolabs 
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Ni-NTA     nickel-nitrilotriacetic acid 
NR      nuclear receptor 
OD      optical density 
PAGE      polyacrylamide gel electrophoresis 
PBS      phosphate buffered saline 
PCR      polymerase chain reaction 
PDB      Protein Data Bank 
pI      isoelectric point 
PMSF      phenylmethanesulfonyl fluoride 
rpm      revolutions per minute 
SDS      sodium dodecyl sulfate 
SOC      super optimal broth with glucose 
ssDNA     single-stranded DNA 
TAE      tris acetate EDTA 
TCEP      tris-(2-carboxyethyl)phosphine 
TEV      Tobacco Etch Virus 
Tris      tris(hydroxymethyl)aminomethane 
UV      ultraviolet 
v/v      volume per volume 
w/v      weight per volume 
(His)6-LXRα/β LBD ligand binding domain of Liver X Receptor as fusion-protein 
with the N-terminal hexahistidine-tagged fusion peptide 
from pRSET B. 
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1  Introduction 
 
Over weight and obesity is a well-known problem in the western world (1), and as rest of the world is 
getting “westernized”, more and more young adults in Asia are overweight or obese (2). A consequence 
of this increase in obesity and overweight is an increase in obesity-related diseases like diabetes, 
atherosclerosis and other cardiovascular diseases (3). A known effect of obesity is the increase in insulin 
resistance, which heightens the risk of developing the previously mentioned diseases. According to the 
National Heart, Lung and Blood institute in the US, atherosclerosis in the coronary arteries is the main 
cause of death of both men and women in the United States of America (4). Studies have also shown that 
an unhealthy diet, which often is the cause of obesity, may lead to cancer (5). A correlation has been 
shown between obesity and colon cancer (6). Cancer is a leading cause of death worldwide and is a 
complex disease dependent on many factors. Naturally there is a high demand for new and improved 
drugs against these diseases, but unfortunately, approval of new drugs is a long and costly process. From 
discovery and modification of potential new drugs to an actual drug on the market, it takes usually 12-15 
years, with an average cost of 4-11 billion dollars per approved drug. Even though the pharmaceutical 
industry is a billion dollar business, competition is high and the discovery of novel drugs is difficult. To 
find novel drugs, it is important to identify the drug targets. With the drug target identified it is possible 
to design drugs that will bind the target and hopefully not much else. Most drugs target proteins as 
agonists or antagonists and manipulate pathways, in which the protein is involved. Drug design has 
traditionally been done in the laboratory by screening for lead compounds, then modifying the hits and 
again screening for the best compounds, but as computers are getting powerful it is increasingly common 
to design and screen for new drugs virtually. Virtual screening has significantly decreased the time spent 
on discovering and designing new drugs, as the computer can sort out promising compounds from 
hundreds of thousands of compounds, leaving only modification and testing of the promising compounds 
as the time consuming steps. However, virtual screening is completely dependent on having the structure 
of the target at hand. Structure determination is achieved by various techniques, with X-ray 
crystallography being the most important. The Protein Data Bank (PDB) is an extremely important tool 
for 21st century drug designers	  (7). As of 2014, over 100000 structures are deposited in the databank, of 
which almost 90% were solved by X-ray crystallography, and the number of deposited crystal structures 
is growing exponentially; from ~4400 structures in 2004 to ~89000 structures in 2014	  (8). A little more 
than 23000 of the structures are of human origin, so there is still a long way to go before structures of all 
the human proteins and variants of them, are available for drug design and modeling.  
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1.1 Transcription Factors 
 
A group of very important human proteins are the transcription factors (9). Transcription factors are 
proteins that modulate the transcription of a gene by either binding to or letting go of the DNA sequence 
adjacent to the regulated gene. Hence the transcription factors are vital for many important cellular 
processes such as development, intercellular signaling and cell cycle (10). As the transcription factor 
family is so large, individual transcription factors work in many different ways. A gene can be directly 
regulated by the transcription factor itself, working as a repressor or activator, or by regulation of the 
synthesis of the named transcription factor. Though many proteins play crucial roles in gene 
transcription, the classification of transcription factors is the presence of one or more DNA-binding 
domains (DBDs). Over 2600 proteins in humans have been identified to contain such DBDs (9). A DBD 
recognizes specific sequences of DNA referred to as response elements and binds them by hydrogen 
bonds and van der Waals forces. The interaction between the transcription factor and the sequence is 
specific, but not all of the bases in the sequence are always involved in the binding, thus making the 
transcription factor able to bind to several sequences that are closely related, with different strengths of 
interaction. However, there are several other factors such as accessibility of response element, and 
obligatory binding partners, making the transcription factor specific, even though response elements 
could randomly occur due to the length of the genome. DBDs are classed in major families e.g. zinc 
fingers, helix-turn-helix motif and basic helix-loop-helix motif to mention a few. As the transcription 
factors are involved in a wide variety of cellular processes, it is not surprising that the alteration in these 
factors can lead to human diseases. Mutations of the DNA or in the transcription factor can lead to 
increased or decreased activity. Development and hormone response disorders, and cancer are related to 
mutations in DNA. Cancer arises due to abnormal cell growth. Cell growth is controlled by a variety of 
factors and proteins, some of which inhibit growth while others stimulate it. This is of course a shallow 
view of cancer, but it is likely that transcription factors are in some way involved in all forms of human 
cancer. Hence transcription factors are interesting as pharmaceutical drug targets. However, it is difficult 
to specifically target some transcription factors with small molecules, as not all transcription factors have 
a ligand-binding domain (LBD). Approximately 13% of all prescription drugs already target the class of 
transcription factors with a ligand-binding domain – the nuclear receptors (11). 
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1.2 Nuclear Receptors 
The nuclear receptors are signal-sensing proteins specific to animals. When a signal molecule is bound to 
the nuclear receptor, it is activated and works as a transcription factor in the nucleus. The two domains of 
the nuclear receptors, DNA-binding domain and ligand-binding domain, are highly and moderately 
conserved, respectively, throughout the animal kingdom. Nuclear receptors are believed to have appeared 
with the first animals, approximately 635 million years ago according to fossil records (12). Now more 
than 900 nuclear receptor genes have been identified in the animal kingdom, but the number of nuclear 
receptor genes varies between species. There are approximately 48 nuclear receptor genes identified in 
human, mouse and rat (13). Nuclear receptors are classified according to the ligands associated with them 
and are called orphan receptors if they have no ligand associated with them. When the ligand associated 
with the receptor is identified, the receptor is “adopted”. The ligands associated with the nuclear receptors 
are hydrophobic molecules that are metabolites from several metabolic pathways, as well as synthetic 
drugs, antibiotics, xenobiotics and lipophilic hormones. Depending on the mechanism of action of the 
nuclear receptor, they are divided into four broad classes. Type I nuclear receptors reside in the cytosol as 
complexes with heat shock proteins (HSPs). When a ligand is bound to the type I receptor, the heat shock 
protein dissociates and the nuclear receptors homo-dimerize. The homodimer then translocates from the 
cytoplasm into the nucleus and binds to specific inverted repeat sequence on the DNA known as response 
element (RE). Other proteins recruited by the receptor-DNA complex transcribe DNA downstream from 
the binding site, thus leading to cellular change (14). Type III nuclear receptors have the same 
mechanism of action as Type I, but instead of binding the inverted repeat RE, they bind the direct repeat 
RE. Type II nuclear receptors reside in the nucleus as complexes with co-repressor proteins. Ligand 
binding causes the co-repressor to dissociate from the nuclear receptor, which then hetero-dimerizes with 
another nuclear receptor, usually Retinoid X Receptor (RXR), and binds to the RE. Co-factors are 
recruited and transcription starts. Type IV nuclear receptors also reside in the nucleus and bind DNA 
either as monomers or dimers, but only one DNA-binding domain binds to a single half site RE. The 
DNA-binding domain, on the N-terminal side of the protein, is the most conserved domain of the nuclear 
receptors and contains two zinc fingers in tandem that consist of approximately 80 amino acid residues in 
total. The zinc fingers each coordinate a zinc ion through four cysteines and are responsible for 
recognizing the correlating RE. The DBD is connected to the ligand-binding domain by a flexible hinge 
region that allows dimerization and DNA binding simultaneously. The ligand-binding domain is also 
conserved, but with variations through the subclasses of nuclear receptors. The first crystal structure of 
the ligand-binding domain of a nuclear receptor is a heterodimer of the Retinoic acid receptor α (RAR) 
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from human and the Retinoid X receptor α from mouse (15). It showed that the LBD consists of 12 α-
helices making a hydrophobic cavity in which hydrophobic ligands can bind. Once a ligand enters the 
cavity, helix 12 closes the cavity by hydrogen bonding to the polar end of the steroid. Although 48 
nuclear receptor genes have been identified in humans, only approximately half of them have been 
classified according to their ligands. The remaining are orphan receptors without known ligands and 
target genes. However, the importance of the nuclear receptors is widely known, as almost every field of 
medicine is affected by disorders related to inappropriate nuclear receptor signaling (16). Nuclear 
receptor disorders include diabetes, atherosclerosis, inflammation, obesity and cancer. The 
hydrophobicity of the ligand-binding domain in the nuclear receptors makes them perfect pharmaceutical 
drug targets, and 13% of modern day pharmacopeia target nuclear receptors. This makes nuclear 
receptors the second biggest drug target, beaten only by the Rhodopsin-like G-protein Coupled Receptors 
(11). The hydrophobicity of the ligands makes it easy to discover and improve new compounds (17). 
Therefore it is important to “adopt” the orphan receptors and obtain structures of the already known 
nuclear receptors. Some of the adopted orphan receptors include fatty acid sensors - the peroxisome 
proliferator-activated receptors (PPAR), the bile acid sensor – Farnesoid X receptor (FXR) and the sterol 
sensors – Liver X Receptor (LXR). 
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1.3 Liver X Nuclear Receptors 
 
The Liver X Receptors were discovered in 1994 and 1995 by isolation from a liver cDNA library, and 
consist of two members, LXRα (NR1H3) and LXRβ (NR1H2). They were given their name from the 
original discovery in the liver and were classified as orphan receptors, but were later adopted when 
organic tissue extracts and natural compounds were screened. The most potent activators identified were 
a group of oxysterols derived from cholesterol metabolism in the brain, adrenal, liver, macrophages and 
gonads. The oxysterols include 22(S/R)-hydroxycholesterol, 24(S),25-epoxycholesterol, 27-
hydroxycholesterol and some bile acids (16). The identification of LXR ligands led to a clearer 
understanding of their roles in metabolism, and structure-activity relationship studies led to the discovery 
of two powerfull synthetic LXR agonists named T0901317 and GW3965 (18, 19). Although identified in 
the liver, the LXRs are expressed in several tissues, with LXRα expressed to a high extent in the liver and 
lower levels in adrenal gland, adipose tissue, intestine, kidney and spleen. LXRβ is ubiquitously 
expressed (20), hence LXRβ is sometimes referred to as ubiquitous receptor. The human LXR isoforms 
are encoded by separate genes, and have been identified to have molecular weights of approximately 
50 kDa with a sequence similarity of 78% in their two domains (21). Reschly et al. showed that LXRs are 
similar throughout the animal kingdom, but that their LDBs have different specificity for vertebrates and 
invertebrates (22). The LXRs are type II nuclear receptors and, when activated, heterodimerize with 
retinoid X receptors (NR2B1, 2B2 and 2B3). The heterodimer binds to a response element characterized 
by direct repeats separated by four nucleotides. The LXR response elements regulate lipid homeostasis. 
LXRs act as cholesterol sensors in the cell and respond to elevated sterol concentrations by induction of 
genes encoding several sterol transporters of the ATP binding cassette transporters A and G 
(ABCA/ABCG), cholesterol ester transfer protein (CETP), cholesterol 7 alpha-hydroxylase (CYP7A) 
apolipoprotein-E (ApoE), fatty acid synthase and acetyl-CoA carboxylase (ACC) (23). This enormous 
variety of target genes makes LXR involved in numerous pathways. Figure 1.3.1 (24) shows an 
illustration of all the metabolic pathways and cell/tissue types modified in response to LXR signaling. 
Several studies with knockout mice have shown the different roles of LXRα and LXRβ (25-27). LXR 
activation with the agonists T0901317 and GW3965 has been shown to be anti-diabetic, induce reverse 
cholesterol transport, suppression of human cancer cell lines of colon, skin and prostate cancer, and a 
suppressing effect on the production of β-amyloid (28-31). However, LXRα has been shown to be 
involved in apoptosis of germ cells, while LXRβ is involved in the proliferation of germ cells (32). The 
activation of LXRα has been shown to raise triglyceride levels in liver and plasma. These joint and 
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separate involvements of LXRs make them ideal and challenging pharmaceutical targets. To be able to 
design drugs that successfully target one of the LXRs both not the other it is important to obtain several 
structures of the LXR LBDs bound to ligands. And several structures of the LXR LBDs are reported with 
different synthetic ligands bound (33-37).  
 
  
Figure 1.3.1. Metabolic pathways and cell/tissue types modified in response to LXR signaling	  (24). 
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1.4 X-ray crystallography and protein purification 
 
 X-ray crystallography 1.4.1
X-ray crystallography is an extremely powerful tool for obtaining 3D structures of macromolecules, and 
is the most common method used for obtaining structures of proteins. The method makes the study of 
molecules on an atomic level with distinction between separate atoms possible. This allows researchers to 
study interaction between molecules in great detail, which is invaluable for our understanding of 
biological molecules and their functions, mechanisms of activation and role in pathways in the body.  
 
The method is based on the fact that in microscopy the wavelength defines the fineness of detail that can 
be observed. Atoms and the bonds between them are in the range of 0.08-0.25 nm, so an appropriate 
wavelength of 0.1 nm has to be used to be able to distinguish details. This wavelength is in the range of γ- 
and X-rays. There is of course no lens that can focus waves in this order of magnitude; the best optical 
microscope has a lower limit of 500 nm, so to be able to distinguish details on an atomic level, coherent 
scattering of X-rays from electrons in the atoms has to be detected. The scattering pattern of the X-rays 
can then be used to calculate the atoms position in space. Scattering from single molecules is not strong 
enough to be detected, thus the scattering has to be amplified. Amplification happens if the molecule is 
symmetrically repeated in a lattice – a crystal (38, 39). To obtain a crystal the molecule has to be obtained 
in pure form. When a crystal of the molecule is obtained it is exposed to X-rays and data sets of 
individual diffraction patterns are collected. These diffraction patterns are used to create electron density 
maps through a series Fourier-transform calculations. The electron density map is then used to build a 3D 
model of the molecule. A basic set up of crystallography is shown in figure 1.4.1.  
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Figure 1.4.1. Basic schematic representation of protein crystallography. The X-ray beam is diffracted by the 
crystal, creating a diffraction pattern that can be used to create an electron density map. The electron density 
map is then used to build a 3D model. 
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 Protein Purification 1.4.2
There are many ways of purifying proteins from their source by taking advantage of the different 
properties of the proteins. Chromatography is used to separate proteins by e.g. size, affinity, charge or 
hydrophobic interactions, to name a few. The rule of thumb being to use as few purification steps as 
possible to obtain high yield of pure, active protein. If the target protein has an unusual isoelectric point 
(pI) and/or molecular weight compared to the indigenous proteins in the production host, the purification 
can be performed with only few steps including e.g. solubility-, pI- or salting out precipitation and size-
exclusion chromatography. However as most proteins are in the same range of pI and molecular weight, 
it is common to fuse an affinity tag onto the target protein by recombinant DNA technology. Affinity 
chromatography separates proteins by reversible interaction between the tagged protein and immobilized 
metal ions or a ligand attached to the chromatography matrix. Affinity chromatography is most 
discriminating and offers high selectivity, intermediate to high capacity and is sometimes efficient 
enough to yield pure protein. If needed, affinity chromatography can be followed by ion exchange 
chromatography (IEX) as a second bulk purification step, and gel filtration (GF), also known as size-
exclusion chromatography, as a final polishing step. This three-step purification strategy is commonly 
used in small-scale purification as well as industrial purification, and in theory will yield highly pure 
active protein. There are many purification tags with corresponding affinity columns available, with 
histidine tagging being one of the most common. Histidine tags are used in immobilized metal ion 
affinity chromatography (IMAC). IMAC is based on the interaction between immobilized divalent metal 
ions and polyhistidine tags in proteins. The affinity for the metal ions is higher with increasing numbers 
of histidine residues. A typical purification using IMAC begins with equilibrating the column with a low 
concentration of imidazole. The imidazole molecules will bind to the immobilized metal ions and become 
the counter ligand. The column is washed with binding buffer to elute the naturally binding proteins in 
the cell lysate. The protein sample is applied to the column in a binding buffer with low concentration of 
imidazole. Then the proteins are eluted using a linear gradient of increasing imidazole concentration. 
Imidazole is the functional group of histidine, hence the imidazole molecules will compete for the nickel 
ions with the His-tagged proteins and displace them from the column. A typical IMAC purification 
chromatogram is shown in Figure 1.4.2 (40). The first peak from the washing of the column comes from 
all the naturally binding proteins, the second peak in the elution comes from the His-tagged fusion 
protein.  
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IEX separates proteins based on the reversible interaction between a charged protein and an oppositely 
charged chromatography medium. The proteins have to be solubilized in a buffer with an appropriate pH 
according to their pI and applied to either an anion- or cation exchanger. The target protein is 
concentrated during the chromatography and can be eluted from the column either by increasing salt 
concentration and/or a changing pH gradient. IEX can be used in all steps of purification, but is not as 
discriminating as IMAC.  
GF separates molecules based on their size, under mild conditions. The sample goes through a column 
packed with material with pores. The molecules are adsorbed in the pores and thus separated by size. 
Small molecules will travel in and out of pores appropriate to their size, while larger molecules will not 
fit in the pores and are eluted right away. GF is a simple purification technique that only requires a single 
buffer and no gradient, giving GF the ability of working within broad ionic strength, pH and temperature 
range. A typical example of His-tagged GF chromatography is shown in figure 1.4.3 (40).  
Figure 1.4.2. A typical chromatogram from IMAC purification with 
gradient elution of His-tagged fusion proteins (40).  
Figure 1.4.3. A typical chromatogram from 
GF purification of a His-tagged target protein 
(40) 
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1.5 Aims of Master’s Project 
 
This Master’s project is a collaboration project with the School of Pharmacy to study the molecular 
mechanism of activation and inhibition of the Liver X Receptors. At the School of Pharmacy there is 
established a synthetic program to identify new, innovative chemical entities that are possible LXR 
ligands. A number of structures of the LXR LBDs with ligands bound are solved, however, most the 
ligands are synthetic. So the current knowledge about the molecular activation mechanism and most of 
the interpretations is based on the structures with synthetic ligands bound. To get a better understanding 
of the LXRs role in lipid homeostasis and be able to do structure-guided drug design, it is important to 
obtain structures of the LXRs bound to endogenous sterols, synthetic sterol derivatives as well as novel 
synthetic ligands. Therefore obtaining a high yield of pure active protein is of interest, as the proteins are 
going to be used in co-crystallization/soaking trials with a diverse library of lead compounds synthesized 
at the School of Pharmacy. 
 
 
This Master’s project focuses on the first steps, of this big project, with the following aims:  
 
Ø Production of the proteins 
Express the proteins recombinant from E. coli cells, purify the proteins by chromatographic 
methods and optimize a protocol for obtaining high yield of pure active protein. 
 
Ø Crystallize the proteins 
Screen for the optimal crystallization conditions of the proteins before doing co-
crystallization/soaking trials with endogenous oxysterols, synthetic oxysterol derivatives, plant 
phytosterols and synthetic novel ligands synthesized at the School of Pharmacy. 
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1.6 Strategies 
 
The Master’s project was designed based on the previously reported structure-related publications of the 
LXR LBDs. The articles were compared and all the reported constructs were the basis for the choice of 
construct. An overview over the articles with their constructs, expression vectors, purification tags, 
ligands in the crystal structures, and PBD entry codes are shown in Table 1.6. The Master’s project is 
subsectioned into different strategies for obtaining pure active protein in high yield. The first strategy was 
designed based on the survey compiled in Table 1.6 and was expected to be straightforward. However, it 
turned out no to be so simple. Hence, several strategies were investigated to obtain pure active protein in 
high yield. Strategies 1, 1B and 1C are based on the original construct, strategy 2 is based on a different 
expression construct. 
 
Table 1.6. A compilation of the techniques used for expression and purification of the previously reported 
structures of LXR LBDs 
Group and 
year 
Protein and 
amino acids 
Expression 
vector 
Purification tag Ligands used in 
crystallization 
PDB 
code 
Färnegård et 
al. 2003 
LXRβ: 213-461 pET28a Thrombin cleavable 
hexahistidine tag 
T0901317 and GW3965 1PQ9, 
1PQC and 
1PQ6 
Fradera et 
al. 2010 
LXRα: 182-447 N/A Non-cleavable hexa-
(histidine-glutamine) 
tag 
GW3965, F3methylAA 
and benzisoxazole urea 
3IPQ, 
3IPS and 
3IPU 
Hoerer et al. 
2003  
LXRβ: 209-461 pET28a(+) Thrombin cleavable 
hexahistidine tag 
T0901317 1UPV and 
1UPW 
Svensson et 
al. 2003 
LXRα: 207-447 
in complex with 
RXRβ  
pET15 Thrombin cleavable 
hexahistidine tag 
LXR agonist T-17 and 
RXR agonist MPA 
1UHL 
Williams et 
al. 2003 
LXRβ: 214-
461 
pRSET A Thrombin cleavable 
hexahistidine tag 
T0901317 and 
24(S),25-
epoxycholesterol 
1P8D 
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 Strategy 1: Expression of the LXR LBDs from the purchased vector 1.6.1
Based on the information compiled in table 1.6 the constructs of the LXR LBDs were decided to be 182-
447 and 216-460 for LXRα and LXRβ, respectively. The theoretical isoelectric points (pI) and molecular 
weights of the proteins are approximately 5.9/30.6 kDa and 5.9/28.6 kDa for LXRα LBD and 
LXRβ LBD, respectively. A quick look at the plot of theoretical molecular weight against pI of the 
indigenous proteins in E. coli in Figure 1.6.1 (41), shows that the LXR LBDs are almost exactly in the 
middle of the plot where most of the native E. coli proteins are. Since the LXR LBDs were going to be 
expressed recombinantly in E. coli, purification would require multiple purification steps without any 
guarantee of yielding highly pure protein. Hence it was desirable to fuse the LXR LBDs to a purification 
tag, making purification possible with very few steps. The three-step purification strategy of purification 
was used in all of the articles of LXR LBD crystal structures (33-37, 42). Recombinant production and 
purification of the LXR LBDs seemed straightforward with a cleavable purification tag fused to the 
proteins. Conveniently LifeTechnologies sold the synthesis and cloning into an expression vector as a 
package deal, and because a cleavable purification tag was desirable, the genes were purchased in the 
pRSET B expression vector (Invitrogen™). This is a pUC-derived expression vector designed for high-
level protein expression in E. coli. The expression of the gene of interest is controlled by the phage T7 
promoter, which is recognized by T7 RNA polymerase. For expression to occur, the lac operon-
controlled T7 RNA polymerase has to be expressed in sufficient amounts. This is inducible by addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to the growth medium. In addition, the vector contains a 
sequence that encodes for an N-terminal fusion peptide. This sequence includes a translation initiation 
codon, a hexahistidine tag, the T7 phage gene 10 leader sequence that stabilizes the transcription of the 
foreign gene, an epitope for the Xpress™ antibody, and an enterokinase cleavage recognition sequence. 
A map and the multiple cloning site of the pRSET B vector are shown in Figure 1.6.2 (43). The 
LXR LBDs were cloned into the vector using the XhoI and KpnI cloning sites. The expected sizes of the 
fusion-proteins are 34.6 kDa and 32.6 kDa for (His)6-LXRα LBD and (His)6-LXRβ LBD, respectively. 
See Appendix; Section A for the full-length sequences. 
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Figure 1.6.1. A plot showing the indigenous proteins of E. coli plotted by theoretical molecular weight against 
theoretical pI (41). 
LXR LBDs 
~coordinates 
	   17	  
 
Figure	  1.6.2.	  The	  map	  and	  multiple	  cloning	  site	  of	  the	  expression	  vector	  pRSET	  B.	  (43)	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 Strategy 1B: in vitro refolding of proteins purified from inclusion bodies 1.6.2
The experiments with recombinant production of the (His)6-LXR LBDs showed that the cells expressed 
the proteins in high amounts, but the proteins aggregated and formed insoluble inclusion bodies. It is 
known that reduced growth rate usually leads to a more soluble expression and reduce inclusion body 
formation. We tried varying the expression time and temperature during the expression, transformed the 
constructs into cold-adapted cells engineered to improve the solubility of proteins prone to aggregation, 
and had a ligand omnipresent during expression, to investigate if this would improve the solubility of the 
(His)6-LXR LBDs, but all the experiments resulted in a high amount of insoluble protein. Inclusion 
bodies are often very pure and if refolding of the proteins in vitro is possible, inclusion body purification 
is a direct and effective method of producing highly purified protein (44). Hence we decided to try 
inclusion body purification and refolding of the proteins in vitro in refolding buffer with and without 
cholesterol. REFOLD is an analytical database that contains methods and protocols for refolding of 
recombinant proteins in vitro (44). The database has over a thousand refolding records stored. 
Unfortunately the LXR LBDs are not among the entries.  
 
 Strategy 1C: subcloning of Tobacco Etch Virus protease cleavage site 1.6.3
into the pRSET B construct 
To circumvent problems experienced with enterokinase cleavage of the His-tag in the pRSET B 
construct, we decided to subclone a novel cleavage site into the construct upstream from the enterokinase 
cleavage site. The new cleavage site would be recognized by Tobacco Etch Virus (TEV) protease. 
Tobacco Etch Virus protease (TEVp) is a highly sequence-specific cysteine protease that recognizes the 
sequence ENLYFQS and cleaves the peptide bond between glutamine and serine. The TEVp cleavage 
site would be subcloned into the construct between the epitope and the enterokinase cleavage site. TEVp 
was the protease of choice because of its high sequence specificity (45), and an in-house bachelor’s thesis 
on the production and purification of Green Fluorescent Protein (GPF)-labeled, hexahistidine-tagged 
TEV protease.  
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 Strategy 2: cloning of the genes in the periplasmic expression vector 1.6.4
pFKPEN 
Expression the LXR LBDs in the pRSET B plasmid were shown to be difficult and rate limiting. 
Strategies 1, 1B and 1C were investigated to optimize and circumvent the problems experienced with the 
construct from the pRSET B plasmids. All of the strategies led to the same conclusion of little or no 
protein purified. For every solution more problems were encountered, so we decided to clone the 
LXR LBD genes into another expression named pFKPEN. Gunnarsen et al. engineered this vector to 
improve the expression of T cell receptors, which were prone to aggregation and proteolysis in bacterial 
systems (46). pFKPEN is optimized for periplasmic bacterial expression and carries the gene encoding 
the periplasmic chaperone FkpA. FkpA is a peptidyl-propyl cis,trans-isomerase that has been shown to 
reactivate inactive proteins and prevent premature aggregation of early folding intermediates. 
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2 Experimental Procedures 
 
 
2.1 Expression of (His)6-LXR LBDs 
 
 
 Expression in BL21DE3 2.1.1
 
Transformation of E. coli BL21DE3 competent cells with the LXR constructs 
Approximately 50 ng of each construct were transformed into 50 µl of competent E. coli BL21 DE3 cells 
by heat shocking the cells at 42 °C for 45 seconds. 500 µl of SOC medium, pre-warmed to 37 °C, was 
added to the cells and the samples were incubated at 37 °C with shaking at 200 rpm, for 1 hour. The cells 
were centrifuged at 16000 × g, and 350 µl of the medium was decanted. The cell pellet was re-suspended 
in the medium remaining in the tube and plated onto LB agar plates containing 100 mg/l ampicillin. 
Plating non-transformed cells onto plates with and without ampicillin added were used as controls. The 
plates were incubated at 37 °C overnight. If the control plates showed positive results (i.e. no growth on 
the ampicillin plate and massive growth on the agar plate), a colony was picked from each transformation 
and inoculated in 5 ml of LB medium with added 100 mg/ml of ampicillin (LBamp) and incubated 
overnight at 37 °C and 120 rpm. 1 ml of each of the overnight cultures were mixed with 0.5 ml 60% 
glycerol and stored at -80 °C as a glycerol stock.  
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Expression of (His)6-LXR LBDs 
Overnight cultures were made from the LXR glycerol stock by inoculating 50 ml of LBamp with a scrap 
of cells, and incubating the samples on a rotary shaker at 37 °C/120 rpm. The overnight cultures were 
used to make main cultures by inoculating 1 l pre-warmed LBamp medium to an OD600 of 0.05. The main 
cultures were incubated on a rotary shaker at 37 °C/110 rpm. OD600 was measured hourly during the 
growth. When the OD600 reached 0.8, the cultures were induced with 0.2 mM IPTG. After 4 hours, for 
normal expression, or 12-24 hours for the overnight expression, the cells were harvested by 
centrifugation at 6000 × g for 15 minutes at 4 °C. The cell pellets were collected and frozen in -80 °C.  
 
Harvest of proteins from the cells 
The frozen pellets were thawed and re-suspended in 15-25 ml lysis buffer (50 mM Tris pH 8.0, 50 mM 
NaCl, 150 µM PMSF with Roche cOmplete Protease Inhibitor Cocktail tablet). Lysozyme was added to 
the sample to a final concentration of 2-4 mg/ml and the samples were incubated at room temperature on 
a shaker for 2-4 hours. A small scrap of deoxyribonuclease I was added to the sample if the sample was 
very viscous. The samples were centrifuged at 45000 × g for 20 minutes at 4 °C, and the supernatant was 
decanted from the pellet. To confirm that the induction had worked, samples of the medium prior to the 
induction, the supernatant and the pellet after harvest were analyzed by SDS-PAGE as described in the 
SDS PAGE protocol below. 
 
SDS-PAGE protocol 
The SDS-PAGE samples taken during the expression and the lysis were dissolved in sample buffer (2% 
SDS, 5% 0.2 mM β-mercaptoethanol, 10% glycerol, 60 mM Tris pH 6.8, 1.4 mg/ml bromphenolblue and 
4M urea) to a total volume of 60 µl, respectively, and heated to 90 °C for 5 minutes. 15 µl of the samples 
were applied to a NuPAGE 4-12% Bis-Tris gel. 5 µl of SeeBlue®Plus 2 (Invitrogen) were used as 
marker, and the gel was run in NuPAGE® Tris MES SDS running buffer for 35 minutes at 
200 V/400 mA/100 W. The gel was stained with Coomassie Blue or using the SilverQuest™ staining kit 
(Invitrogen)  
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  Expression in ArcticExpress cells 2.1.2
 
The LXR LBD constructs were transformed into ArcticExpress competent cells (Agilent Technologies) 
as described in Section 2.1.1. Two different protocols were tested for the expression of the His-tagged 
LXR LBDs in the ArcticExpress cells. The protocol described in Section 2.1.2, and Agilent 
Technologies’ ArcticExpress optimized-expression protocol (47).  
 
Standard expression protocol 
An expression test was set up for both BL21DE3 cells and ArcticExpress cells transformed with the 
pRSET B LXR LBD constructs. The expression was performed overnight at 30 °C and 12 °C, for 
BL21DE3 and ArcticExpress cells, respectively. The overnight cultures were harvested and lysed.  
 
Expression protocol optimized for ArcticExpress 
Pre-cultures of LBamp medium with gentamycin added to a concentration of 20 µg/l were inoculated 
with a scrap of ArcticExpress cells from the glycerol stocks. The pre-cultures were incubated overnight 
on a rotary shaker at 37 °C/200 rpm. The overnight pre-cultures were diluted 1:50 into LB medium with 
no selection of antibiotics as main cultures and incubated for 3 hours on a rotary shaker at 30 °C/200 rpm. 
The main cultures were transferred to a rotary shaker with a temperature of 12 °C and incubated for 
approximately 10 minutes (so the cells had some time to acclimatize) at 200 rpm. IPTG was added to a 
final concentration of 1 mM and the cultures were incubated for 24 hours. The cells were harvested and 
lysed as described in Section 2.1.2 
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2.2 Purification of (His)6-LXR LBDs 
 
The recombinant proteins were fused with an N-terminal hexahistidine tag for purification by 
immobilized metal ion affinity chromatography (IMAC) as a first step for capturing the proteins. Gel 
filtration chromatography was used as a second purification step.  
 
 Column preparation  2.2.1
HiTrap Chelating HP (GE) 5 ml columns were used for capturing the proteins of interest, with a separate 
column prepared for each protein. Prior to use the columns were pre-washed with 3 column volumes 
(CV) of distilled water using a syringe. For charging with Ni2+ ions, the columns were loaded with ½ CV 
of 0.1 M NiSO4. The columns were then washed with 3 CV of distilled water. The columns were placed 
on the ÄKTApurifier FPLC system (GE Healthcare) and equilibrated by washing with 5-10 CV of 
binding buffer (50 mM sodium phosphate, pH 7.5, 400 mM NaCl, 100 mM KCl, 0.25 mM TCEP, 
150 µM PMSF, 20 mM imidazole).  	  
 Protein purification by FPLC 2.2.2
The supernatant from the lysed cells was applied to the columns using a pump, and the columns were 
washed with 5-10 CV of binding buffer (400 mM NaCl, 150 µM PMSF, 50 mM NaH2PO4, 100 mM KCl, 
20 mM imidazole). The proteins were eluted and collected in fractions of 1.0 ml, using a linear gradient 
of increasing concentration of elution buffer (binding buffer with 500 mM imidazole and 1 mM DTT). 
10 µl of the fractions from the peaks in the chromatogram were mixed with 10 µl of SDS sample buffer 
and analyzed by SDS-PAGE as described in Section 2.1.2. Fractions containing the protein of interest 
were pooled and concentrated in a centrifugal concentrator unit with polyethersulfone membrane and 
either 5 kDa or 10 kDa molecular weight cut-off filters (MWCO) (Vivaspin 20 from Sartorius Group). 
The buffer was exchanged to a low-salt, low-imidazole buffer (25 mM Tris pH7.6, 100 mM NaCl, 1 mM 
DTT). The concentrated protein sample (0.5 ml) was applied to a SuperDex200 10/300 GL column (GE 
Healthcare) using a 1 ml loop and eluted with elution buffer (25 mM Tris pH 7.6, 100 mM NaCl, 1 mM 
DTT) in fractions of 1 ml. The peaks in the chromatogram were analyzed by SDS-PAGE. The fractions 
containing the protein of interest were pooled and concentrated in a centrifugal concentrator. 
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 Cleavage of the His-tag with enterokinase  2.2.1
 
The ligand binding domains of the LXR isoforms were cloned into a vector as a fusion protein with an N-
terminal purification peptide, as suggested by the LifeTechnologies. The fusion peptide contains a 
hexahistidine tag separated from the proteins by an epitope and an enterokinase cleavage site. The 
cleavage tests were carried out according to the protocol for EnterokinaseMax™ (EKMax™) (48). 
Purified protein concentrated to 0.4 mg/ml was used for a cleavage test with EKMax™. Six reactions 
were set up at four different temperatures, respectively. The temperatures were 37 °C, room temperature, 
16 °C and 4 °C. The room temperature sample was put on the lab bench. The setup for the reactions is 
shown in Table 2.2.1. The reactions were mixed and placed in their respective temperatures overnight. 
The digestion samples were analyzed by SDS-PAGE. 
 
Table 2.2.1: The setup for the EKMax™ digestion test of (His)6-LXRα LBD 
 
	  
A	   B	   C	   D	   E	   F	  
EKMax™ (µl) 0.0 1.0 µl of D 1.0 µl of D 1.0 µl of E 1.0 4.0 
1X EKMax™-buffer (µl) 0.0 9.0 9.0 9.0 9.0 0.0 
10X EKMax™-buffer (µl) 3.0 2.0 2.0 2.0 2.0 3.0 
MQ-H2O (µl) 14.5 5.5 5.5 5.5 5.5 10.5 
(His)6-LXRα LBD (µl) 12.5 12.5 12.5 12.5 12.5 12.5 
Total (µl) 30.0 30.0 30.0 30.0 30.0 30.0 
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2.3 Robotic crystal screening 	  
Screening for crystallization conditions was performed using the vapor diffusion technique with a sitting-
drop setup using the JCSG+ suite and Morpheus® crystallization screens (Qiagen and Molecular 
Dimension, respectively). The sitting drops were dispensed in MRC 2 Well Crystallization Plates 
(Swissci from Hampton Research) by mixing 0.15 µl and 0.3 µl of the (His)6-LXRα LBD protein mix and 
0.15 µl and 0.3 µl of the precipitant solution from pre-dispensed reservoirs for JCSG+ suite and 
Morpheus® screens, respectively. The plates were sealed with crystal clear tape to prevent evaporation. 
The plates were stored in a dark room at 20 °C. 
 
2.4 Refolding of the proteins in vitro, and avoiding 
aggregation 
 
 Purification and refolding of proteins expressed as inclusion bodies 2.4.1
The pellets from the protein expression were re-suspended in CelLytic™ B (Sigma) at a ratio of 10 ml 
per gram of wet pellet. The suspensions were incubated on a shaker in room temperature for 15 minutes 
and then centrifuged at 16000 × g for 10 minutes to pellet the residual insoluble material. The 
supernatants were saved for analysis and the pellets re-suspended in CelLytic™ B 10x. The extraction 
was repeated until it was difficult to dissolve the residual pellets, which took four to five repetitions. 
Finally the pellets were dissolved by sonication in denaturing buffer (8 M urea, 0.5 M NaCl, 20 mM 
sodium phosphate buffer, pH 7.4). The samples were centrifuged at 16000 × g and the supernatants were 
decanted. The proteins were refolded by slowly dripping the supernatants into rapidly stirred refolding 
buffer (0.1 M Tris, 0.4 M L-arginine, 0.150 mM PMSF, 1.0 mM DTT). The refolded protein samples 
were concentrated in a centrifugal concentrator with 10 kDa MWCO and stored overnight at 10 °C. 
Precipitation occurred overnight, so the samples were filtered through a sterile syringe filter (0.45 µm 
polyethersulfone membrane from VWR®) and stored overnight at 10 °C. The samples were further 
purified by IMAC. 
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 Expression, inclusion body purification and refolding of proteins in 2.4.2
presence of cholesterol 
 
Expression 
An overnight pre-culture was set up for (His)6-LXRα LBD and (His)6-LXRβ LBD from the glycerol 
stocks as described in 2.1.2. Main cultures of 1 l LBamp were inoculated and grown to an OD600 of 1.0. 
Ethanol was saturated with cholesterol at a concentration of 0.052 M (49). The stock solution of 
cholesterol was added to the cultures to a final cholesterol concentration of 20 µM. The samples were 
induced by addition of 0.2 mM IPTG. 1.5 hours later more stock solution was added to the cultures to a 
final cholesterol concentration of 40 µM. After two hours the temperature in the incubator was lowered 
from 37 °C to 18 °C and the expression continued overnight. The cells were harvested and lysed as 
described in Section 2.1.2.  
 
Inclusion body purification 
The pellets were re-suspended in 20 ml buffer containing 50 mM HEPES-NaOH pH 7.5, 0.5 M NaCl, 
1 mM PMSF, 5 mM DTT and 0.35 mg/ml lysozyme, and incubated at 20 °C for 30 minutes. Triton X-
100 was added to a concentration of 1% (v/v), and the samples were sonicated until the solutions were 
clear. Deoxyribonuclease I was added to a concentration of 20 mg/l and the samples were incubated at 
37 °C for 1 hour. The inclusion bodies were pelleted by centrifugation at 30 min/30000 × g/4 °C. The 
pellets were washed twice with PBS containing 1% Triton X-100 followed by centrifugation at 
30 min/30000 × g/4 °C. The pellets were solubilized in 2 ml of buffer containing 50 mM HEPES-NaOH 
pH 7.5, 25 mM DTT, 6 M guanidine HCl and incubated at 4 °C for 1 hour. The samples were centrifuged 
at maximum speed (75000 × g) for 10 minutes to remove insoluble material that could act as nuclei to 
trigger aggregation during folding.  
 
Refolding in presence of cholesterol 
The solubilized proteins were rapidly diluted 1:100 in stirred refolding buffer (50 mM HEPES-NaOH 
pH 7.5, 0.2 M NaCl, 1 mM DTT, 0.5 M L-arginine, 50 µM cholesterol). The mix was stirred for 
2 minutes after addition of protein. The samples were kept at 4 °C for 1 hour. Samples from the inclusion 
body purification and refolding were analyzed by SDS-PAGE. 
 
	   27	  
2.5 Subcloning of Tobacco Etch Virus (TEV) protease 
cleavage site into the pRSET construct 
 
 Linearization of the vector 2.5.1
Enzyme master mixes were made with 4 units of XhoI and BamHI. 6 µl of the enzyme master mixes were 
mixed with 750 ng of the plasmids with (His)6-LXRα LBD and (His)6-LXRβ LBD, respectively, and 
incubated at 37 °C overnight. Calf-intestinal alkaline phosphatase (CIP) was added to every sample to a 
concentration of 0.5-1 units per µg DNA, and the samples were incubated at 37 °C for one hour. The 
reaction was quenched by heating to 80 °C for 20 minutes. The samples were purified by agarose gel 
electrophoresis as described in the following section. Samples of uncut plasmid were used as a reference.  
 
Agarose gel electrophoresis 
The samples were mixed with loading buffer and applied to a 0.8% low melting point agarose gel with 
0.5 µg/ml ethidium bromide added. 5 µl of Perfect DNA™ 1 kbp ladder (Novagen) was applied to the gel 
and the electrophoresis ran for 1 hour at 80 V. The gel was examined using the PhotoDoc-It™ 60 
Imaging system with Benchtop UV M-20 Transilluminator (UVP), photographed with Canon PowerShot 
A480, and the interesting DNA bands were cut out. The DNA was purified using the QIAquick Gel 
Extraction Kit (Qiagen) following the protocol from the kit. 
 
 Hybridization of ssDNA oligonucleotides to form double stranded insert 2.5.2
2 µl of the forward and backward oligonucleotides, respectively, coding for the TEV protease cleavage 
site were mixed with 2 µl of 10X ligase buffer and 2 µl of 0.5 M NaCl to a total volume of 20 µl with 
MQ-H2O. The sample was placed in boiling water for 2 minutes, before cooling to room temperature in 
the water bath.  
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 Ligation 2.5.3
The concentrations of linearized plasmids and hybridized insert were determined by measuring the 
absorption at 260 nm using NanoPhotometer® from IMPLEN. The insert and plasmid were mixed in 
ratios of 1:1 and 1:1.5 and added 0.5 µl T4 DNA ligase and 1 µl 10X T4 DNA ligase buffer in a total 
volume of 10 µl. The ligation reactions were incubated at 16 °C overnight. The reaction was quenched by 
heating to 80 °C for 20 minutes.  
 
The samples were transformed into Stellar™ cells (Clontech) as described in Section 2.1.1. The plasmids 
were transformed into the cells in amounts of 1 µl and 2 µl. The cells were plated onto LBamp agar plates 
and incubated at 37 °C. The plates were checked for growth, and promising colonies were picked and 
inoculated in LBamp and incubated overnight at 37 °C/120 rpm. The plasmids were purified from the 
overnight samples with QIAprep Spin Miniprep Kit (Qiagen) and the concentrations of the plasmids were 
determined by spectrophotometry. The samples were mixed with T7 promoter standard primer and sent to 
an in-house sequencing service.  
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2.6 Cloning of the LXR LBD genes into the pFKPEN 
periplasmic expression vector 
 
To improve the solubility of the LXR LBDs it was decided to clone the LXR LBD genes into a new 
vector, pFKPEN, coding for periplasmic translocation and co-expression of a protein to help with folding, 
the periplasmic chaperone FkpA (46). The vector was a kind gift from Geir Åge Løset (Department of 
Biosciences – The Faculty of Mathematics and Natural Sciences, University of Oslo). The cloning was 
done using the In-Fusion® HD cloning kit (Clontech). Primers for amplifying the LXR LBD genes were 
designed according to the In-Fusion kit’s specifications at the Clontech homepage and ordered from 
Eurofins MWG Operon. Forward and reverse primers were designed for cloning the LXR LBD genes 
into the new vector both with a C-terminal hexahistidine tag and without a tag. For the primer sequences 
see Appendix, Section C.  
 
 PCR to amplify the LXR LBD genes and add overlapping ends 2.6.1
The concentrations of the primers were determined by spectrophotometry and stock solutions of 10 µM 
were made. PCR mixes were prepared for the template DNA of (His)6-LXRα LBD and (His)6-
LXRβ LBD from the pRSET B constructs, to generate the inserts without and with His-tag before the In-
Fusion cloning procedure. The setup for the mixes is shown in Table 2.6.1. To generate the His-tag, the 
PCR was performed twice with different primers. For the PCR conditions see Appendix, Section C. 
Table	   2.6.1.	  The	  setup	  for	  the	  PCR	  of	  (His)6-­‐LXRα	  LBD	  and	  (His)6-­‐LXRβ	  LBD	  to	  generate	   inserts	  without	  and	  with	  His-­‐tag	  before	  the	  In-­‐Fusion	  reaction	  
Component 50 µl reaction (µl) 
10X standard Taq reaction buffer 5.0 
10 mM dNTP’s 1.0 
10 µM forward primer 1.0 
10 µM reverse primer 1.0 
Template DNA 2.0 
Taq DNA Polymerase 0.25 
MQ-H2O 39.75 
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 Linearization of pFKPEN expression vector 2.6.2
XL1 Blue CuCl2 cells (Stratagene) transformed with the pFKPEN plasmid were obtained from Geir Åge 
Løset, via the hands of Master’s student Hedda Johannesen. The pFKPEN plasmid was isolated from the 
cells using the miniprep kit (Qiagen) with a final elution in 30 µl of elution buffer. 1000 ng of the 
plasmid were used for linearization. The plasmid was linearized by double digestion with the restriction 
enzymes NcoI and NotI (FastDigest from Fermentas) according to the FastDigest protocol (50). The 
digestion reactions were incubated for 30 minutes at 37 °C. The PCR products and the linearized vector 
were purified by agarose gel electrophoresis, as described in Section 2.5.1. Undigested pFKPEN was 
used as a reference in the electrophoresis. The fragments were purified from the gel pieces using the 
miniprep kit with a final elution of 30 µl of elution buffer.  
 
 Cloning procedure 2.6.3
The PCR fragments for the LXR LBDs, with and without His-tag, and the linearized vector were used for 
the In-Fusion cloning procedure. The control insert and the pUC19 control vector included in the kit were 
used as positive control. The linearized pFKPEN vector was used as negative control. The cloning 
procedure was performed following protocol I:B of the In-Fusion® HD Cloning Kit User Manual (51). 
The samples were incubated for 15 minutes at 50 °C, then placed on ice. The samples from were 
transformed into Stellar™ cells (Clontech) as described in Section 2.1.1. The transformed cells were 
plated out on LBamp agar plates and incubated at 37 °C overnight. The plates were checked for colonies 
and a number of positive colonies from the LXR LBDs plates were inoculated in 5 ml of LBamp. The 
inoculated samples were incubated at 37 °C overnight. The LXR LBD plasmids were purified from the 
overnight cultures using the miniprep kit with a final elution of 30 µl of elution buffer.  
 
 Verification by restriction digest and validation by sequencing 2.6.4
The purified plasmids were analyzed by diagnostic restriction digest before sequencing. The NEBcutter 
V2.0 web tool (52) was used to analyze all of the original sequences and new sequences for the 
LXR LBD genes in their respective plasmids, against restriction enzymes available in the lab and their 
respective number of cleavage sites. Compatible restriction enzymes and their cleavage sites in the 
plasmids are shown in Table 2.6.1. Restriction enzymes AccI and KpnI (FastDigest from Fermentas) were 
used for all plasmids of the digestion test. The digestion reactions were incubated for 30 minutes at 
37 °C, before the samples were analyzed by agarose gel electrophoresis, as described in Section 2.5.1. 
Five random cloning samples were mixed with forward and backward sequencing primers, respectively, 
and sent to an in-house sequencing service. For the primers used see Appendix, Section C. 
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Table	  2.6.1.	  Compilation	  of	  restriction	  enzyme	  cleavage	  sites	  in	  the	  plasmids.	  
	  
Enzyme and 
cleavage site 	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Plasmid AccI BamHI EcoRI HindIII KpnI NcoI NdeI NotI XbaI XhoI 
Original pFKPEN 
(4806bp) 
431, 699, 
1202, 
2263 
1034, 
1344 
131, 
1334 638 
808, 
828, 
906, 
1005 216 - 1026 1097 1 
pFKPEN LXRα 
LBD (4806 bp) 
1202, 
2263 
1034, 
1344 
131, 
1344 - - 216 853 1026 1097 1 
pFKPEN LXRα 
LBD-(His)6 
(4824bp) 
1220, 
2281 
1052, 
1362 
131, 
1352 - - 216 853 1044 1115 1 
pRSET (His)6-
LXRα LBD 
(3685bp) - 192 
1009, 
1024 1031 1019 1019 837 - 158 201 
pFKPEN LXRβ 
LBD (4755bp) 
1151, 
2212 
983, 
1293 
131, 
1283 - - 216 - 975 1046 1 
pFKPEN LXRβ 
LBD-(His)6 
(4773) 
1169, 
2230 
1001, 
1311 
131, 
1301 - - 216 - 1993 1046 1 
pRSET (His)6-
LXRβ LBD 
(3628bp) - 192 967 974 962 962 98 - 58 201 
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3 Results and Discussion 
 
The aim of this master’s project was to produce, purify and crystallize the ligand binding domains 
(LBDs) of the two isoforms, α and β, of Liver X Nuclear Receptors (LXRs). Obtaining crystals for X-ray 
experiments with ligands soaked in or co-crystallized was the ultimate goal. LXR LBDs have been 
successfully purified, crystallized and their structure solved by X-ray crystallography in several groups 
(33-37, 42, 53). The results and discussions will be subsectioned based on three strategies for expressing 
and purifying pure LXR LBDs.  
 
3.1 Strategy 1: Expression, purification and crystallization 
of LXR LBDs in pRSET B vector 
 
 Expression of (His)6-LXRα LBD and (His)6-LXRβ LBD in BL21DE3 3.1.1
cells 
 
The pRSET B vectors with the LXR LBD genes were transformed into BL21DE3 cells and expressed in 
LBamp medium for 4 hours, or 12-24 hours. The cells were harvested and lysed as described in Section 
2.1.2. The induction and harvesting was analyzed by SDS-PAGE. The gels are shown in Figures 3.1.1.1 
and 3.1.1.2. The gels showed that the proteins were inducible, and expressed in high amounts. The 
soluble fractions of the proteins were used for the purification experiments. Figure 3.1.1.2 shows that 
there is a lot of protein remaining in the cell pellet after lysis. This indicates that the proteins aggregate 
and form inclusion bodies in the cells. It is possible to purify the aggregated protein from the inclusion 
bodies, but refolding the protein in vitro gives no guarantee when it comes to structural integrity of the 
protein. We decided to transform the constructs into a bacterial strain engineered for expressing 
recombinant protein at low temperatures called ArcticExpress (Agilent Technologies) to investigate if 
this would help with the aggregation issue. 
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Figure 3.1.1.2. Coomassie stained SDS gel showing the 
lysis stages of BL21DE3 cells expressing (His)6-LXRα 
LBD and (His)6-LXRβ LBD. The samples were pelleted 
twice to extract more protein in the supernatant. 
Lanes:  
1. Molecular weight marker;  
2. Supernatant from the first pelleting of LXRα.  
3. Pellet from the first pelleting of LXRα. 
4. Supernatant from the second pelleting of LXRα.  
5. Pellet from the second pelleting of LXRα. 
6. Supernatant from the first pelleting of LXRβ.  
7. Pellet from the first pelleting of LXRβ. 
8. Supernatant from the second pelleting of LXRβ. 
9. Pellet from the second pelleting of LXRβ. 	  
 Figure 3.1.1.1 Coomassie stained SDS gel 
showing the expression of (His)6-LXRα LBD and 
(His)6-LXRβ LBD in BL21DE3 E. coli cells. A: 
Samples pre-induction, B: Samples taken after 
cell harvesting.  
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 Expression of (His)6-LXRα and (His)6-LXRβ in ArcticExpress competent 3.1.2
cells. 
 
ArcticExpress (AE) is E. coli cells engineered for improved protein processing at low temperatures. 
These cells co-express the cold-adapted chaperonins Cpn10 and Cpn60 from the psychrophilic bacterium 
Oleispira Antarctica. These chaperonins have 74% and 54% sequence identity to the E. coli chaperonins 
GroEL and GroES, respectively. The sizes of the chaperonins are, as the names suggest, 10 kDa and 
60 kDa respectively. An expression test of the ArcticExpress cells was performed according to the 
standard expression protocol described in Section 2.1. The ArcticExpress cells were incubated at 12 °C 
during expression. The result of the SDS-PAGE analysis is shown in Figure 3.1.2.1. The gels show that 
there is no expression of the LXR LBDs in the ArcticExpress cells when following the standard Bl21DE3 
expression protocol at low temperature. An ArcticExpress-optimized expression protocol, from Agilent 
Technologies, was investigated (47). 
 
 
 
Figure 3.1.2.1. Coomassie stained SDS gels showing the stages of expression and lysis of (His)6-LXRα LBD 
and (His)6-LXRβ LBD in BL21DE3 (A#) and ArcticExpress (B#) cells. Lanes: 1, Pre-induction; 2, Before 
harvesting the cells; 3, Pellet before lysis; 4, Pellet after lysis; 5, Supernatant after lysis. 	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The expression of the LXR LBDs in ArcticExpress was performed at 12 °C for 24 hours, before the cells 
were harvested and lysed as described in Section 2.1.2. The result of the SDS-PAGE analysis is shown in 
Figure 3.1.2.2. The gel shows that the ArcticExpress cells do not express the LXR LBDs. The small band 
visible on the gel around approximately 31 kDa is due to the addition of deoxyribonuclease I during the 
lysis. We do not know why the ArcticExpress cells did not express the proteins. An explanation would be 
that the cells might have lost the plasmid. We decided it was not worth the time to pursue the 
ArcticExpress experiment since the choice of constructs probably were responsible for the aggregation of 
the proteins, hence ArcticExpress cells give no guarantee of improving the aggregation. 
 
 
Figure 3.1.2.2. Coomassie of SDS gel showing the stages of 
expression and lysis of (His)6-LXRα and (His)6-LXRβ expressed 
in ArcticExpress cells at 12 °C. 
Lanes:  
1. Pre-induction 
2. The cell medium before harvest 
3. Cell pellet after lysis  
4. Supernatant after lysis  	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 Expression of (His)6-LXRβ LBD within one day at steady temperatures. 3.1.3
 
Experiments with expression of (His)6-LXR LBDs showed high aggregation in vivo, and precipitation in 
vitro under varying temperatures (See 3.2 – Inclusion body purification). Fradera et al. successfully 
purified the LXRα LBD, but mentions under the methods and materials section that all of the purification 
steps were performed within one day at 4 °C. This sentence might indicate that Fradera et al. experienced 
solubility and precipitation issues. We decided to investigate if expression and purification of (His)6-
LXRβ LBD within one day, at steady temperature would significantly improve the issue of in vivo 
aggregation and in vitro precipitation. The expression of (His)6-LXRβ LBD was performed according to 
the original protocol (Section 2.1), except that the sample was immediately taken for the next step 
without any storing in fridge or freezer. Deoxyribonuclease I was added during lysis due to high 
viscosity, the cells were pelleted twice to extract more protein, and the supernatants were pooled. After 
harvest, the supernatant was immediately applied on an equilibrated, nickel loaded IMAC column and 
eluted in 1.0 ml fractions, without knowing if the supernatant contained any of the protein. A zoomed 
version of the chromatogram from the IMAC purification is shown in Figure 3.1.3.1. The peak in the 
flow-through shoulder and the early elution peak were analyzed by SDS-PAGE. The results of the SDS-
PAGE analyses of expression and harvest samples and the elution peaks are shown in the Figures 3.1.3.2 
and 3.1.3.3. 
 
Figure	   3.1.3.2.	   Coomassie	   stained	   SDS	   gel	  showing	   the	   stages	   of	   expression	   and	   lysis	   of	  (His)6-­‐LXRβ	  LBD	   all	   performed	  within	   one	  day.	  The	   sample	  was	   pelleted	   twice	   to	   extract	  more	  protein	  and	  the	  supernatants	  pooled.	  	  
Lanes:  
1. Pre-induction 
2. The cell medium before harvest 
3. First supernatant after lysis  
4. Second supernatant after lysis  
5. Cell pellet after lysis. 	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Figure	   3.1.3.1.	   The	   zoomed	   chromatogram	   of	   the	   peaks	   from	   elution	   of	   (His)6-­‐LXRβ	   LBD	   from	   a	   HiTrap	  Chelating	  HP	  column	  loaded	  with	  nickel.	  Green	  graph:	  concentration	  of	  elution	  buffer.	  Blue	  graph:	  absorption	  at	   280	  nm.	   Red	   graph:	   absorption	   at	   254	  nm.	   Vertical-­‐axis:	   absorbance	   displayed	   in	   milli	   absorbance	   units.	  Horizontal-­‐axis:	  elution	  buffer	  volume	  measured	  in	  milliliters.	   
U
N
ICO
RN
 5
.11
 (B
uild
 407)
R
esult
 file:
 d
:\
.
.
.\d
ani\LX
Rb
eta\LX
Rb
eta
 co
n
secutiv
ely
 exp
ressio
n
 IEX
 H
iT
rapQ
 X
L5
m
l
 G
radientS
am
pleP
u
m
p001
 LXRbeta consecutively expression IEX HiTrapQ XL5ml GradientSamplePump001:10_UV1_280nm
 LXRbeta consecutively expression IEX HiTrapQ XL5ml GradientSamplePump001:10_UV2_254nm
 LXRbeta consecutively expression IEX HiTrapQ XL5ml GradientSamplePump001:10_Conc
 LXRbeta consecutively expression IEX HiTrapQ XL5ml GradientSamplePump001:10_Fractions
   0
 200
 400
 600
 800
1000
1200
mAU
40.0 50.0 60.0 70.0 ml
A7 A8 A9 A11 A13 A15 B2 B3 B4 B5 B6 B7 B8 B9 B11 B13 B15 C2 C3 C4 C5 C6 C7 C8 C9
Flow-­‐through	   Wash	  
	  38	  
 
The gel in Figure 3.1.3.2 shows that the protein is highly expressed after induction, but that all of the 
protein remains in the pellet after lysis even though all temperature variations were kept to a minimum 
during the experiment. The gel in Figure 3.2.3.3 shows that the first peak (flow-through) in the 
chromatogram is due to the high concentration of lysozyme in the sample and that the second peak in the 
chromatogram is not even protein. This experiment shows that the construct for (His)6-LXRβ LBD is 
highly unstable and aggregates in vivo. 
Figure	   3.1.3.3.	   Coomassie	   stained	   SDS	   gel	   showing	   the	   analyzed	   peaks	   from	   the	  chromatogram	  in	  Figure	  3.1.3.1.	  The	  fractions	  from	  the	  chromatogram	  are	  shown	  in	  the	  figure.	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 Expression of pRSET B constructs in presence of cholesterol 3.1.4
 
Hoerer et al. found that the original expression test of LXRβ LBD yielded predominantly insoluble 
protein, and the soluble fraction was unstable and could not be suitably concentrated for protein 
crystallization (35). Addition of the synthetic ligand, T0901317, omnipresent during expression, 
purification and crystallization stabilized the protein significantly. We decided to do an experiment with 
ligand omnipresent during expression, and added cholesterol to all solutions and buffers during the 
expression. Cholesterol was chosen as the ligand because it is cheap and the aim of this master’s project 
is to obtain structures of the LXR LBDs with oxysterols bound. If the result from the cholesterol 
experiments looked promising, other oxysterols could tried be used during expression. Cholesterol is a 
lipid molecule that is required to maintain both membrane structural integrity and fluidity in eukaryotic 
cell, however, it is almost completely absent among prokaryotes, so supplying cholesterol in the growth 
medium of the E. coli cells will lead to a decrease in the membrane fluidity. A publication by Moreno et 
al. investigated the influence of incorporating cholesterol in the growth medium of E. coli (54). They 
found that cholesterol in ethanol solution could be supplemented to the cells to a concentration of 40 µM 
before co-precipitation of cholesterol and cells occurred. LXR LBDs were produced as according to the 
original protocol (Section 2.1). Ethanol saturated with cholesterol was added to the cultures before 
induction to a final concentration of 40 µM. The expression was incubated overnight at 18 °C. The result 
of the SDS-PAGE analysis is shown in Figure 3.1.4.1. The gel shows that the incorporation of cholesterol 
during the expression had no effect on the aggregation of the proteins.  
Figure 3.1.4.1. Coomassie of SDS gel showing the stages of expression and lysis of His-tagged LXR LBDs 
expressed in the presence of cholesterol at 18 °C. The molecular weight marker is given in kDa.  
Lanes:  
1. Pre-induction 
2. The cell medium before harvest 
3. Cell pellet after lysis 
4. Error in application 
5. Supernatant after lysis 	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 Purification of the soluble (His)6-LXR LBDs by IMAC and GF 3.1.5
 
The purification was performed for both isoforms of the LXR LBDs. The cell extract from the expression 
was applied to a nickel-loaded affinity column (HiTrap Chelating HP from GE Healthcare). His-tags have 
a high affinity for Ni2+, this ensures that the fusion proteins bind to the column resin. To elute the 
proteins, imidazole-containing buffers were used. A linear gradient of increasing imidazole concentration 
was used for the elution, and fractions were collected. A zoomed version of a chromatogram from one of 
the (His)6-LXRα LBD IMAC purifications is shown in Figure 3.1.5.1. In the figure a small peak is visible 
in the middle of the elution. Fractions from the wash, the first peak and the elution peak were analyzed by 
SDS-PAGE. The result of the analysis is shown in Figure 3.1.5.2. Fractions B9 to C1 were pooled and 
concentrated in a centrifugal concentrator with 5 kDa MWCO (Vivaspin 20 from Sartorius) to a volume 
of 200 µl. The sample was loaded on a size-exclusion column (SuperDex200 10/300 GL from GE 
Healthcare) and eluted in 1 ml fractions. A zoomed version of the chromatogram from the size-exclusion 
chromatography is shown in Figure 3.1.5.3. Fractions from the first two peaks in the chromatogram were 
analyzed by SDS-PAGE. After Coomassie Blue staining of the gels, the bands were barely visible, so the 
gels were stained using the SilverQuest™ staining kit (Invitrogen). The gel from the second peak showed 
nothing, indicating that this peak is due to salt, which is supported by the conductivity. The gel from the 
first peak is shown in Figure 3.1.5.4. Fractions A4-A12 were pooled, diluted 1:2 with MQ-H2O and 
concentrated to a volume of approximately 125 µl. The concentration of (His)6-LXRα LBD was 
determined to be 6 mg/ml.  
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Figure	  3.1.5.2.	  Coomassie	  stained	  SDS	  gel	  showing	  the	  analyzed	  fractions	  possibly	  containing	  (His)6-­‐LXRα	  LBD	   from	   the	   chromatogram	   in	   Figure	   3.1.5.1.	   The	   fraction	   numbers	   from	   the	  chromatogram	  are	  shown	  in	  the	  figure.	  	  	  
Figure	  3.1.5.1.	  The	  zoomed	  chromatogram	  of	  the	  peaks	   from	  elution	  of	  (His)6-­‐LXRα	  LBD	  from	  a	  HiTrap	  Chelating	   HP	   column	   loaded	   with	   nickel.	   Green	   graph:	   concentration	   of	   elution	   buffer.	   Blue	   graph:	  absorption	   at	   280	  nm.	   Red	   graph:	   absorption	   at	   254	  nm.	   Vertical-­‐axis:	   absorbance	   displayed	   in	   milli	  absorbance	  units.	  Horizontal-­‐axis:	  elution	  buffer	  volume	  measured	  in	  milliliters.	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Figures	   3.1.5.4.	   Silver	   stain	   of	   SDS	   gel	   showing	   the	   analyzed	  fractions	   from	   the	   purification	   of	   (His)6-­‐LXRα	  LBD	   on	   a	  SuperDex200	  10/300	   column.	   The	   corresponding	   chromatogram	   is	  shown	  in	  Figure	  3.1.5.3.	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   (His)6-­‐LXRα	  LBD.	   Green	   graph:	   concentration	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   elution	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   Brown	   graph:	   conductivity.	   Blue	   graph:	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   at	   280	  nm.	   Red	   graph:	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   at	   254	  nm.	   Vertical-­‐axis:	   absorbance	   displayed	   in	   milli	  absorbance	  units.	  Horizontal-­‐axis:	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  buffer	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 Cleavage of the His-tag with enterokinase 3.1.6
 
The LXR LBDs were purchased as fusion proteins with an N-terminal hexahistidine tag separated from 
the proteins by an epitope and an enterokinase cleavage site. Enterokinase is a serine protease that 
recognizes the sequence Asp-Asp-Asp-Asp-Lys and cleaves the peptide bond after the lysine residue. 
EnterokinaseMax™ (Invitrogen) was used for cleaving off the His-tag. EKMax™ is a recombinant 
preparation of the catalytic subunit of bovine enterokinase produced and purified from the yeast, Pichia 
pastoris, yielding an enzyme with higher specific activity than the native version (48). The construct 
(His)6-LXRα LBD has an expected theoretical size of approximately 34.6 kDa, and after cleavage of the 
His-tag the expected theoretical size would be 30.6 kDa. Purified soluble (His)6-LXRα LDB was used for 
the enterokinase cleavage test. An assay was setup to screen for the suitable cleavage conditions varying 
the amount of protease used and temperature (See Table 2.2.1). The samples were analyzed by SDS-
PAGE. The result of the analysis is shown in Figures 3.1.6.1 and 3.1.6.2. 
	  	  
Figures	  3.1.6.1.	  Coomassie	  stained	  SDS	  gel	  showing	  the	  result	  of	  a	  cleavage	  test	  performed	  at	  37	  °C	  and	  room	  temperature,	  with	  enterokinase	  on	  purified	  (His)6-­‐LXRα	  LBD.	  A	  to	  F	  shows	  increasing	  amounts	  of	  protease	  used	  for	   the	   digestion.	   Table	   2.2.1	   shows	   detailed	   reaction	   parameters	   for	   the	   cleavage	   test.	   The	   molecular	   weight	  marker	  is	  in	  kDa	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The expected results from the cleavage test would be that the 34.6 kDa fusion protein band fading and 
another band appearing at 30.6 kDa for increasing amounts of enterokinase. The figures show that the 
34.6 kDa fusion protein band is fading, but there is no band appearing right below. There are however 
several bands appearing at approximately half the size of the fusion protein band. These results indicate 
that enterokinase is unspecific when cleaving the protein. Although the manufacturer claims enterokinase 
to be highly specific, it has been shown that this is not the case (55-57). Liew et al. showed that 
enterokinase was compromised by non-specific cleavage at three other sites than the expected DDDDK, 
and that one of the secondary sequences was cleaved at greater efficiency. Shahravan et al. found that 
changing several parameters, pH, temperature, the amount of EK used, did not prevent the unspecific 
hydrolysis. These authors suspected that aggregation impeded the accessibility of the enterokinase 
cleavage site and tried to add denaturant to the cleavage buffer. This addition reduced the unspecific 
hydrolysis, but did not prevent it entirely. Furthermore, the addition of denaturants like urea to the 
reaction buffer has an inhibitory effect on the activity of enterokinase at higher concentrations. Hosfield 
and Lu found that by addition of aspartic acid directly downstream of the enterokinase target site, they 
obtained 84% cleavage. Shahravan et al. had an aspartic acid directly downstream of the target site in 
their sequence, and this did not affect the cleavage rate. The additional cleavage sequences discovered by 
Liew et al. are not in the LXR LBD sequences, but as enterokinase is so highly unspecific, there might be 
additional unknown enterokinase cleavage sites in the LXR LBD sequences that are similarly or more 
efficient than the canonical DDDDK. 
Figures	   3.1.6.2.	   Coomassie	   stained	  SDS	  gel	   showing	   the	   result	  of	   a	   cleavage	   test	  performed	  at	  16	  °C	  and	  4	  °C,	  with	  enterokinase	  on	  purified	  (His)6-­‐LXRα	  LBD.	  A	  to	  F	  shows	  increasing	  amounts	  of	  protease	  used	  for	  the	  digestion.	  Table	  2.2.1	  shows	  detailed	  reaction	  parameters	  for	  the	  cleavage	  test.	  The	  molecular	  weight	  marker	  is	  in	  kDa.	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 Robotic crystal screening 3.1.7
The purified (His)6-LXRα LBD from the soluble fraction was used for a crystallization trial, to 
investigate if the N-terminally tagged protein could be directly used for crystallization trials, without 
removing the tag. The protein mix contained approximately 5.9 mg/ml (His)6-LXRα LBD, 25 mM NaCl, 
7 mM Tris pH 8.0 and >0.5 mM DTT. The crystal screens used were the JCSG+ suite (Molecular 
Dimenstions) and Morpheus® (Molecular Dimensions). The screens were set up in 96 well plates (MRC 
2 Well Crystallization Plates from Swissci) using the Oryx 4 crystallization robot. They were stored in a 
dark room at 20 °C, and regularly inspected. After four months a crystal appeared in the JCSG+suite 
under the conditions: 0.2 M lithium sulfate, 0.1 M Bis-Tris pH 5.5, 50% PEG400. The droplet is shown 
in Figure 3.1.7.1. The biggest crystal in the droplet was fished, frozen in a cryostream and tested at 
European Synchrotron Research Facility in Grenoble France. The initial X-ray data showed that the 
crystal was salt. Even with big amounts of pure protein, obtaining protein crystals is one of the biggest 
challenges in protein crystallography. In this case, the concentration of pure protein was relatively low, 
and in addition the N-terminal purification tag was still on the protein. This flexible tag might prevent the 
proteins from coming together in an ordered way and forming crystals.  
 
 
Figure	  3.1.7.1	  A	  picture	  of	  (His)6-­‐LXRα	  LDB	  in	  the	  JCSG+	  Suite	  crystallization	  screen	  under	  the	  conditions:	  0.2	  M	  lithium	  sulfate,	  0.1	  M	  Bis-­‐Tris	  pH	  5.5,	  50%	  PEG400	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Conclusion of Strategy 1 
Strategy 1 was based on the assumption that the expression and purification of the LXR LBDs would be 
straightforward. The gene lengths were designed based on the articles on crystal structures of LXR LBDs 
(33-35, 37, 42) and out of convenience purchased in the pRSET B expression vector as this vector 
encodes a N-terminal fusion peptide on the protein with a hexahistidine purification tag separated from 
the protein by an enterokinase cleavage site. The enterokinase was reported it to be highly specific. The 
original expression tests with the constructs in 1 l medium yielded little or no soluble protein. For (His)6-
LXRα LBD, the final concentration after two-step chromatography purification was determined to be 
5.9 mg/ml in a volume of 125 µl, giving a yield of 0.73 mg. For (His)6-LXRβ LBD, no pure protein was 
obtained from the soluble fraction, as the protein was lost during purification. Scaling the expression up 
was considered, but cleavage of the purification tag had to be facilitated with enterokinase. The 
enterokinase digestion test on (His)6-LXRα LBD showed that enterokinase is highly unspecific at a 
variety of temperatures and concentrations. Enterokinase has also been found to be highly unspecific 
when varying the pH (55). Optimization of enterokinase digestion is possible by adding or deleting 
residues downstream or upstream of the canonical cleavage site of enterokinase, but appears to be 
protein-specific, and may not be applied to all fusion proteins. Shahravan et al. found that denaturing 
conditions under enterokinase digestion could improve the unspecific cleavage, which would denature the 
target protein and require refolding in vitro. The experiments with expression showed that the proteins 
were overexpressed, but most of the proteins were in an insoluble fraction after harvest. We decided to 
isolate the (His)6-LXR LBDs from the inclusion bodies and do an in vitro refolding of the proteins 
(Strategy 1B). We decided to circumvent the enterokinase issues by introducing a new cleavage site for 
Tobacco Etch Virus protease (TEVp) into the sequence by subcloning (Strategy 1C). The crystallization 
test with (His)6-LXRα LBD did not yield protein crystals. Obtaining protein crystals can often be 
unpredictable, so it cannot be claimed that the absence of crystals is due to crystallization conditions, 
protein concentration or the flexible N-terminal fusion peptide on the LXRα LBD. Histidine tags may be 
advantageous in crystallization as the tag allows coordination of the protein to nickel ions, if present, in 
the mother liquor. In this construct the hexahistidine section is separated from the protein by an epitope 
and an enterokinase cleavage site. When the sequences of the constructs were run through the 
Multilayered Fusion-Based Disorder Predictor – Web Server (58), the results predicted with a score of 99 
that the fusion peptide tail (47 residues) and the N-terminal regions of the proteins are disordered. This 
high level of disordered residues on the terminal of the proteins is definitely not advantageous for crystal 
formation and points to that the purification tag has to be removed from the protein before crystallization. 
We decided to optimize purification and purification-tag cleavage before doing more crystallization trials. 
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3.2 Strategy 1B: in vitro refolding of inclusion body purified 
proteins 
 
 Purification and refolding of proteins expressed as inclusion bodies 3.2.1
Inclusion body purification was performed in parallel for both of the LXR LBD isoforms. Figures for 
(His)6-LXRα LBD are not shown. The cell pellet from the normal expression was used for the inclusion 
body experiment. The inclusion bodies were extracted by washing the pellet in CelLytic B and dissolved 
in highly concentrated urea buffer. The SDS PAGE analysis of the samples taken during the purification 
is shown in Figure 3.2.1.1. The proteins were refolded by rapid dilution into buffer, without and with 
50 µM cholesterol, and no denaturants. During the refolding of the proteins in presence of cholesterol, 
immediate precipitation was observed in the (His)6-LXRβ LBD sample. (His)6-LXRα LBD precipitated 
after stirring for one hour in presence of cholesterol. The refolded protein samples, from refolding 
without cholesterol, were purified by IMAC on a nickel-loaded column. A close up view of the 
chromatogram from the analysis is shown in Figure 3.2.1.3. Fractions J8-K4 were analyzed by SDS-
PAGE (Figure 3.2.1.2). Coomassie staining did not give good enough sensitivity, so the gels were silver 
stained. The gel shows that the peak from the chromatogram contained (His)6-LXRβ LBD and some 
impurities. The fractions containing the protein were pooled and the protein concentrations in the pooled 
samples were determined to be 0.1 mg/ml and 0.4 mg/ml for (His)6-LXRα LBD and (His)6-LXRβ LBD, 
respectively. The proteins were concentrated in a centrifugal concentrator unit with 10 kDa MWCO 
(Vivaspin 20 from Sartorius). During the concentration, the proteins precipitated.  
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Figure	  3.2.1.1.	  Coomassie	  stained	  SDS	  gel	  showing	  the	  inclusion	  body	  extraction	  of	  (His)6-­‐LXRα	  LBD	  and	  (His)6-­‐LXRβ	  LBD.	  
Lanes:	  
α1:	  Supernatant	  of	  (His)6-­‐LXRα	  LBD.	  
*1:	  Error	  in	  application.	  
β1:	  Supernatant	  of	  (His)6-­‐LXRβ	  LBD.	  
*2:	  Error	  in	  application.	  
	  α2:	  Pellet	  of	  (His)6-­‐LXRα	  LBD.	  
β2:	  Pellet	  of	  (His)6-­‐LXRβ	  LBD	  
Figure	  3.2.1.2.	  Silver	  staining	  SDS	  gel	  showing	  the	  analyzed	  fractions	  containing	  inclusion	  body	  isolated	  (His)6-­‐LXRβ	  LBD	  from	  the	  chromatogram	  in	  Figure	  3.2.1.2.	  The	  fraction	  numbers	  from	  the	  chromatogram	  are	  shown	  in	  the	  figure.	  Molecular	  weight	  marker	  is	  in	  	  kDa.	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Conclusion of Strategy 1B 
This experiment showed that it is possible to isolate the (His)6-LXR LBDs from the inclusion bodies 
formed during expression, but the precipitation of the protein during concentration indicates that 
inclusion body purified protein is not stable in solution, even at low concentrations. The results from the 
inclusion body experiments indicate that the constructs are unstable and aggregate. Refolding of the 
constructs in vitro might be possible, but this requires searching for optimized conditions, which might be 
a relatively random process. The constructs might require a binding partner, a co-activator peptide or a 
ligand to be stabilized, which is hard to predict in advance of the experiments. We concluded that the 
optimization of the refolding would be to time consuming and economically unfavorable to pursue and 
decided to scale up the expression if the subcloning of a new cleavage site in the construct was 
successful.  
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   Zoomed	  chromatogram	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   elution	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  LBD	   from	   the	  HiTrap	  Chelating	  HP	  column	  loaded	  with	  nickel.	  Blue	  graph:	  absorption	  at	  280	  nm.	  Red	  graph:	  absorption	  at	  254	  nm.	  Green	  graph:	   concentration	   of	   imidazole.	   Vertical-­‐axis:	   absorbance	   displayed	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  milli	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   Horizontal-­‐axis:	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  buffer	  volume	  measured	  in	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3.3 Strategy 1C: Subcloning of Tobacco Etch Virus protease 
cleavage site into the pRSET construct 
 
The sequences of the oligonucleotides for the TEVp cleavage site used for the subcloning were 5’-TCG 
AGC GAA AAC CTG TAT TTC CAG GGC-3’ and 5’-TCG AGC CCT GGA AAT ACA GGT TTT 
CGC-3’ for the forward and backward oligos respectively. The pRSET B plasmids with the (His)6-
LXR LBD genes were linearized by double digestion with XhoI and BamHI and purified by agarose gel 
electrophoresis (Figure 3.3.1). Undigested plasmids were used as a reference.  
 
The concentrations of the agarose gel-purified linearized plasmids were determined by spectrophotometry 
to be 14 ng/µl and 12 ng/µl for (His)6-LXRα LBD and (His)6-LXRβ LBD, respectively. The newly 
hybridized oligos were determined by spectrophotometry to have a concentration of 636 ng/µl. The 
linearized plasmids and double stranded oligos were ligated, transformed into Stellar™ cells (Clontech) 
and plated on LBamp plates. Promising colonies were picked and used to inoculate 5 ml cultures, which 
were grown overnight at 37 °C. The plasmids were purified from the cells using QIAprep Spin Miniprep 
Kit (Qiagen). Nineteen samples were sequenced by an in-house sequencing service. The results were 
compared with the original (His)6-LXR LBD plasmids, and showed that none of the sequenced samples 
contained the TEVp cleavage site.  
 
 
Figure	  3.3.1.	  A	  0.8%	  agarose	  gel	  showing	  supercoiled	  and	  linearized	  pRSET	  B	  plasmids.	  A#:	  with	  LXRα	  LBD	  gene.	  B#:	  with	  LXRβ	  LBD	  gene.	  1:	  undigested	  plasmid.	  2:	  double	  digested	  plasmid	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Conclusion of Strategy 1C 
This experiment was conducted several times with the same negative result. None of the sequenced 
samples contained the TEVp cleavage site. The pRSET B vector contains an N-terminal fusion peptide 
fused to the LXR LBDs, as described in Strategy 1. As experiments have shown these constructs tend to 
aggregate and form insoluble inclusion bodies during expression with little or no soluble protein left in 
the supernatant. The addition of the TEVp cleavage site would lead to reliable cleavage of the tag, but as 
all of the experiments with pRSET B plasmids have been dead ends and required further optimization, we 
decided to try and circumvent all of the experienced problems and clone the genes into another 
expression vector coding for periplasmic expression, see Strategy 2.  
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3.4 Strategy 2: cloning of the LXR LBD genes into the 
pFKPEN periplasmic expression vector 
 
The periplasmic expression vector was a kind gift from Geir Åge Løset (Department of Biosciences – 
The Faculty of Mathematics and Natural Sciences, University of Oslo) obtained via the hands of Master’s 
student Hedda Johannesen, in XL1 Blue CuCl2 cells (Stratagene). The In-Fusion HD cloning kit 
(Clontech) was used for the cloning reactions. This kit is designed for fast, directional cloning of one or 
more fragments of DNA into any vector by fusing PCR-generated fragments into linearized vectors using 
the In-Fusion enzyme premix that recognizes a 15 base pair (bp) overlap at the ends of the fragments and 
vectors. One set of primers was designed for amplifying the LXR LBD genes, and one set of primers was 
designed for adding a C-terminal hexahistidine tag on the LXR LBDs. All primers were designed to 
generate a 15 bp overlap with the pFKPEN vector on both termini of the LXR LBD genes. The 
hexahistidine tag was designed to be non-cleavable. The pRSET B plasmids were used together with the 
primers for PCR. To engineer the C-terminal hexahistidine tag the samples were amplified twice, first to 
add the His-tag, then to add the 15 bp overlap with pFKPEN. The pFKPEN plasmid was purified from 
the cells and linearized by double digestion with NcoI and NotI. The PCR products and linearized vector 
were purified by agarose gel electrophoresis (Figure 3.4.1 to Figure 3.4.3). Due to high amounts of 
sample the LXRα LBD-(His)6 and LXRβ LBD-(His)6 samples were loaded in two wells, respectively. 
The lengths of the genes and linearized plasmid are 814 bp, 763 bp and 3996 bp for LXRα LBD, 
LXRβ LBD and pFKPEN, respectively. The band at approximately 4 kbp in Figure 3.4.1 was purified 
and the concentration of the linearized plasmid was determined by spectrophotometry to be 6.5 ng/µl. 
The PCR products were determined to have DNA concentrations of 20 ng/µl, 77 ng/µl, 2.5 ng/µl and 
10 ng/µl for LXRα LBD, LXRβ LBD, LXRα LBD-(His)6 and LXRβ LBD-(His)6, respectively.  
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Figure	  3.4.1.	  A	  0.8%	  agarose	  gel	  	  showing	  pFKPEN	  undigested	  (U),	  single	  and	  double	  (D)	  digested	  with	  NotI	  (S1)	  and	  NcoI	  (S2)	  
Figure	  3.4.2.	  A	  0.8%	  agarose	  gel	  showing	  the	  PCR	  products	  of	  LXR	  LBDs.	  	  
Fig.3.5.2.	  	  
α:	  LXRα	  LBD	  with	  15	  bp	  overlap	  to	  pFKPEN.	  
α	  H1:	  LXRα	  LBD	  with	  C-­‐terminal	  hexahistidine	  tag.	  
β:	  LXRβ	  LBD	  with	  15	  bp	  overlap	  to	  pFKPEN.	  
β	  H1:	  LXRβ	  LBD	  with	  C-­‐terminal	  hexahistidine	  tag.	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 The In-Fusion cloning and transformation procedure was performed according to protocols VI:B and 
VIII, respectively, of the In-Fusion® HD Cloning Kit User Manual (Clontech) (51). 50-100 ng of the 
PCR products and linearized plasmid were used for the cloning procedure. The controls were positive, i.e. 
the positive control showed more than hundred colonies on the LBamp plate and the negative control 
showed a few colonies. The LXRα LBD-(His)6 plate was overgrown. 5 colonies were picked from 
LXRα LBD and LXRβ LBD, respectively. 24 colonies were picked from LXRβ LBD-(His)6. The 
colonies were grown in LBamp and purified by miniprep. Diagnostic restriction digest was done to verify 
if the cloning procedure was successful. The restriction digest was done with the restriction enzymes AccI 
and KpnI. See Table 2.6.1 for the cleavage sites of the restriction enzymes in the different vectors. The 
samples of each cloned plasmid was single digested by the restriction enzymes, respectively. The original 
pFKPEN plasmid purified from the XL1 Blue cells was used as a reference and digested accordingly. 
Undigested samples were loaded on the gel as references. All samples were applied to the gel in the order 
of undigested, KpnI-digested and AccI-digested. One of the gels is shown in Figure 3.4.4. All of the gels 
were inconclusive and showed the same pattern as α1 and α2 the gel in Figure 3.4.4. The original, 
undigested, pFKPEN plasmid, with a size of 4.8 kbp, appears above the 10 kbp band of the weight 
marker in Figure 3.4.4, but at the expected size in Figure 3.4.1. However the cleavage pattern in Figure 
3.4.4 is as expected for both the restriction enzymes. No conclusion could be drawn, as the reference 
samples are inconsistent in all of the gels. A diagnostic restriction digest gives only a verification 
expectation, but the samples would still have to be sequenced for a validation. Five random samples were 
picked for in-house sequencing. The samples were mixed with forward and backward sequencing 
primers, respectively, yielding ten samples. The sequencing primers used had the sequences 5'-
CGGATAACAATTTCACACAG-3' and 5'-CTAGATTAGTGATGGTGATG-3', forward and backward 
respectively. The sequencing results did not contain any signal, but the background noise was present.  
Figure	  3.4.3.	  A	  0.8%	  agarose	  gel	  showing	  the	  second	  PCR	  products	  of	  LXR	  LBDs	  with	  C-­‐terminal	  hexahistidine	  tag.	  Due	  to	  high	  amounts	  of	  sample	  two	  wells	  were	  used,	  respectively.	  The	  his-­‐tagged	  PCR	  products	  from	  Fig.3.5.2	  were	  added	  a	  15	  bp	  overlap	  to	  pFKPEN	  in	  the	  second	  PCR.	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Figure	  3.4.4.	  A	  0.8%	  agarose	  gel	  showing	  the	  results	  of	  a	  diagnostic	  restriction	  digest	  of	  cloning	  experiments	  with	  LXR	  LBD	  genes,	  with	  and	  without	  C-­‐terminal	  His-­‐tag,	  in	  pFKPEN	  plasmid.	  All	  of	  the	  samples	  were	  applied	  in	  the	  same	  order.	  U:	  undigested.	  K:	  KpnI	  single	  digested.	  A:	  AccI	  single	  digested.	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Conclusion of Strategy 2 
To circumvent all the issues experienced with expressing LXR LBD genes in the vector pRSET B we 
decided to clone the genes into pFKPEN periplasmic expression vector. pFKPEN is engineered to 
improve aggregation and proteolysis experienced with bacterial expression systems. The vector carries 
the gene encoding for a periplasmic chaperone shown to improve folding and prevent aggregation of 
recombinant proteins. In addition the genes cloned into the vector are N-terminally fused to a pelB signal 
sequence that directs protein translocation to the periplasm of the E. coli cell. The amplification of the 
genes and the linearization of pFKPEN were successful, but the cloning procedure yielded inconclusive 
results. The sequenced plasmid samples from the cloning procedure gave results without signal, but with 
background noise present. The in-house sequencing service that performed the sequencing of the samples 
were going out of business, and the sequencing of the samples was done on the day after the announced 
last day of the service. It is difficult to say if the inconclusive sequencing results are due to error in the 
service, the primers or the samples. Although a diagnostic restriction digestion test performed on the 
samples points to that the samples contained the wrong plasmid. No conclusions could be drawn from the 
digestion test due to unexpected and unexplainable patterns in the gels. The gels showed the known 
reference plasmid at double the expected size, but this anomaly was consistent throughout all gels. If we 
assume that something went wrong with the gels or the electrophoresis, the results of the digestion test 
indicates that all, except two, of the samples contained the original pRSET B plasmid and not the target 
pFKPEN plasmid. The expected digestion pattern of the newly generated plasmids would be undigested, 
and two bands for the restriction enzymes KpnI and AccI, respectively. Expected digestion pattern for the 
pRSET B plasmid would be a linearized DNA band, and undigested DNA band for KpnI and AccI, 
respectively. The gels showed the pRSET B expectation for all samples except two (α3 and α4 in Figure 
3.4.4). These samples might show the pFKPEN expectation, but it is hard to say for sure because of 
smeary bands. The presence of pRSET B in the samples should not have happened as the PCR products 
were purified from the agarose gel, before being used for another PCR. The contamination might have 
come from the lab equipment, but it seems unlikely as the procedures of the experiments were conducted 
on different days. Unfortunately this was the last experiment in the project and there was no more time to 
conduct further analysis of the cloned samples.  
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4 Summary and future considerations 
 
The aim of this Master's project was to express, purify and crystallize the ligand-binding domains of the 
Liver X Receptors, α and β, in their native forms and bound to a variety of ligands. The work from the 
Master’s project would be used for structural studies and drug design, to find promising compounds 
against maladies related to lipid homeostasis. Several structures of the LXR LBDs bound to different 
ligands are reported in the PDB, but all the ligands are synthetic. Hence the ultimate goal of this Master’s 
project was to obtain several crystals of the LXR LBDs bound to endogenous oxysterols and novel 
synthetic ligands, synthesized at the School of Pharmacy. Based on previous work on the LXR LBDs, it 
was expected that the biggest workload would lie in the crystallization and ligand soaking of the crystals, 
with the possibility of synthesis of potential ligands if there was enough time. This was, however, not the 
case. The purchased constructs of the LXR LBDs gave rise to more problems than we anticipated. Thus 
the main part of the Master’s project became the optimization of expression and purification.  
 
The purchased constructs expressed in high yield, but little of the protein was soluble. To avoid 
aggregation and inclusion body formation during the expression of the proteins, we tried to vary the 
temperature, expression time and add a ligand to all solutions when expressing the proteins in the 
standard expression strain E. coli BL21 DE3 and we tried to express the proteins in cold-adapted E. coli 
optimized for expression of proteins prone to aggregation. All of the experiments yielded little or no 
soluble protein. The soluble protein was successfully purified, but in low yields. Scaling up the 
expression could have increased the yield, but the proteins had a long disordered hexahistidine 
purification tag on the N-terminus separated form the LBDs by an enterokinase cleavage site. Cleavage 
experiments with enterokinase showed that it is highly unspecific at varying temperatures and with 
varying amounts of protease used. The replacement of amino acids adjacent to the cleavage site was 
reported to significantly increase the specificity of enterokinase (56, 59). However, this seems to be 
protein specific and may not be the solution for all fusion proteins (55). Removal of the tag could be 
unnecessary as a histidine-tag sometimes can be advantageous for crystallization by coordination of the 
proteins with nickel-ions in the mother liquor, so we tried to directly crystallize the purified tagged 
LXRα LBD protein, but the screen did not yield any protein crystals. The highly disordered purification 
tag still on the protein might have prevented crystal formation. We tried to circumvent the problems 
experienced with enterokinase by subcloning a novel cleavage site in the constructs encoding cleavage 
with Tobacco Etch Virus protease. In parallel with experiments of in vitro refolding of aggregated 
proteins. If these strategies had worked, they could be combined to obtain high yields of pure tag-less 
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protein. Unfortunately the subcloning did not go as expected, and the refolding yielded unstable protein 
that aggregated when concentrated to medium concentration. The experiments with optimization of the 
constructs had reached its limit, so we tried to clone the genes into a new expression vector encoding 
periplasmic translocation and a periplasmic chaperone to prevent aggregation. The expression system was 
developed by Gunnarsen et al. to improve expression of proteins prone to aggregation. The vector was a 
kind gift from Geir Åge Løset (Department of Biosciences – The Faculty of Mathematics and Natural 
Sciences, University of Oslo). The vector was successfully linearized by double restriction digestion and 
the genes were successfully amplified by PCR with ends overlapping with the linearized vector. 
However, the cloning procedure yielded ambiguous results. The samples from the cloning procedure 
were analyzed by restriction digestion and DNA-sequencing, and both results indicated that the cloned 
samples contained the old vector. Unfortunately the time had run out for the Master’s project, so no more 
experiments were conducted on the cloned samples.  
 
This Master’s project shows that expression, purification and crystallization of recombinant proteins will 
not always go as expected. Although the ultimate goals of the project were not reached, a lot has been 
learned along the way. Considerations for future work in this project would be to do more experiments on 
the cloned samples, and if required repeat amplification of the genes to generate a short TEVp-cleavable 
N-terminal hexahistidine tag and repeat the cloning procedure. The periplasmic expression system was 
originally developed for T cell receptors, so it is unknown if the system will work for the LXR LBDs, but 
as the LXR LBDs also are prone to aggregation in bacterial systems it is likely that periplasmic 
expression with a chaperone would increase the yield of soluble protein. Co-expression with RXR could 
also be tried out to improve the solubility. Once pure active protein is obtained, it is strongly advised to 
crystallize the proteins in presence of the SRC-1 co-peptide and/or binding partner RXR and the ligand of 
choice. 
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Appendix 
Section A: sequences of LXR LBD genes and amino acids 
 
DNA sequence of LXRα LBD 
CAGGAGGAGGAGCAGGCCCACGCCACCAGCCTGCCCCCCAGGGCCAGCAGCCCCCCCCAG 
ATCCTGCCCCAGCTGAGCCCCGAGCAGCTGGGCATGATCGAGAAGCTGGTGGCCGCCCAG 
CAGCAGTGCAACAGGAGGAGCTTCAGCGACAGGCTGAGGGTGACCCCCTGGCCCATGGCC 
CCCGACCCCCACAGCAGGGAGGCCAGGCAGCAGAGGTTCGCCCACTTCACCGAGCTGGCC 
ATCGTGAGCGTGCAGGAGATCGTGGACTTCGCCAAGCAGCTGCCCGGCTTCCTGCAGCTG 
AGCAGGGAGGACCAGATCGCCCTGCTGAAGACCAGCGCCATCGAGGTGATGCTGCTGGAG 
ACCAGCAGGAGGTACAACCCCGGCAGCGAGAGCATCACCTTCCTGAAGGACTTCAGCTAC 
AACAGGGAGGACTTCGCCAAGGCCGGCCTGCAGGTGGAGTTCATCAACCCCATCTTCGAG 
TTCAGCAGGGCCATGAACGAGCTGCAGCTGAACGACGCCGAGTTCGCCCTGCTGATCGCC 
ATCAGCATCTTCAGCGCCGACAGGCCCAACGTGCAGGACCAGCTGCAGGTGGAGAGGCTG 
CAGCACACCTACGTGGAGGCCCTGCACGCCTACGTGAGCATCCACCACCCCCACGACAGG 
CTGATGTTCCCCAGGATGCTGATGAAGCTGGTGAGCCTGAGGACCCTGAGCAGCGTGCAC 
AGCGAGCAGGTGTTCGCCCTGAGGCTGCAGGACAAGAAGCTGCCCCCCCTGCTGAGCGAG 
ATCTGGGACGTGCACGAG 
 
Amino acid sequence of LXRα LBD 
QEEEQAHATSLPPRASSPPQILPQLSPEQLGMIEKLVAAQQQCNRRSFSDR 
LRVTPWPMAPDPHSREARQQRFAHFTELAIVSVQEIVDFAKQLPGFLQLSREDQIALLKT 
SAIEVMLLETSRRYNPGSESITFLKDFSYNREDFAKAGLQVEFINPIFEFSRAMNELQLN 
DAEFALLIAISIFSADRPNVQDQLQVERLQHTYVEALHAYVSIHHPHDRLMFPRMLMKLV 
SLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE* 
 
DNA sequence of LXRβ LBD 
 
GGTGAAGGTGAAGGCGTTCAGCTGACCGCAGCACAAGAACTGATGATTCAGCAGCTGGTTGCAGCAC
AGCTGCAGTGTAATAAACGTAGCTTTAGCGATCAGCCGAAAGTTACCCCGTGGCCTCTGGGTGCAGA
TCCGCAGAGCCGTGATGCACGTCAGCAGCGTTTTGCACATTTTACCGAACTGGCAATTATTAGCGTGC
AAGAGATTGTGGATTTTGCCAAACAGGTTCCGGGTTTTCTGCAGCTGGGTCGTGAAGATCAGATTGCA
CTGCTGAAAGCAAGCACCATTGAAATTATGCTGCTGGAAACCGCACGTCGCTATAATCATGAAACCG
AATGTATCACCTTCCTGAAAGATTTCACCTATAGCAAAGATGATTTTCATCGTGCAGGTCTGCAGGTC
GAATTTATCAATCCGATTTTTGAATTTAGCCGTGCAATGCGTCGTCTGGGTCTGGATGATGCAGAATA
TGCCCTGCTGATTGCCATTAACATTTTTAGCGCAGATCGTCCGAATGTTCAAGAACCGGGTCGTGTTG
AAGCACTGCAGCAGCCGTATGTGGAAGCGCTGCTGAGCTATACCCGTATTAAACGTCCGCAGGATCA
GCTGCGTTTTCCGCGTATGCTGATGAAACTGGTTAGCCTGCGTACCCTGAGCAGCGTTCATAGCGAAC
AGGTTTTTGCACTGCGTCTGCAGGATAAAAAACTGCCTCCGCTGCTGTCAGAAATTTGGGATGTTCAT
GAATAA 
 
Amino acid sequence of LXRβ LBD 
 
GEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFT 
ELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKD 
FTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRV 
EALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPL LSEIWDVHE*  
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DNA sequence of pFKPEN vector obtained from Geir Åge Løset with the gene for 14F7 antibody in 
italics 
 
    CTCGAGAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT TAGCTCACTC 
   51 ATTAGGCACC CCAGGCTTTA CACTTTATGC TCCCGGCTCG TATGTTGTGT 
  101 GGAATTGTGA GCGGATAACA ATTTCACACA GAATTCATTA AAGAGGAGAA 
  151 ATTAACCATG AAATACCTAT TGCCTACGGC AGCCGCTGGC TTGCTGCTGC 
201 TGGCAGCTCA GCCGGCCATG GCCCACCACC ACCACCACCA CGAAAACCTG 
 TACTTCCAGG GTCAGGTGCA GCTGCAGCAG AGCGGCGCGG AACTGGCGAA  
 ACCGGGCGCG AGCATGAAAA TGAGCTGCCG CGCGAGCGGC TATAGCTTTA  
 CCAGCTATTG GATTCATTGG CTGAAACAGC GCCCGGATCA GGGCCTGGAA  
 TGGATTGGCT ATATTGATCC GGCGACCGCG TATACCGAAA GCAACCAGAA  
 ATTTAAAGAT AAAGCGATTC TGACCGCGGA TCGCAGCAGC AACACCGCGT  
 TTATGTATCT GAACAGCCTG ACCAGCGAAG ATAGCGCGGT GTATTATTGC  
 GCGCGCGAAA GCCCGCGCCT GCGCCGCGGC ATTTATTATT ATGCGATGGA  
 TTATTGGGGC CAGGGCACCA CCGTGACCGT GAGCAGCAAG CTTTCAGGGA  
 GTGCATCCGC CCCAAAACTT GAAGAAGGTG AATTTTCAGA AGCACGCGTA  
 GACATCCAGA TGACCCAGAC CCCGTCTTCT CTGTCTGCTT CTCTGGGTGA 
 CCGTGTTACC ATCTCTTGCC GTGCTTCTCA GGACATCTCT AACTACCTGA  
 ACTGGTACCA GCAGAAACCG GACGGTACCG TTAAACTGCT GATCTACTAC  
 ACCTCTCGTC TGCACTCTGG TGTTCCGTCT CGTTTCTCTG GTTCTGGTTC  
 TGGTACCGAC TACTCTCTGA CCATCTCTAA CCTGGAACAG GAAGACATCG  
 CTACCTACTT CTGCCAGCAG GGTAACACCC TGCCGCCGAC CTTCGGTGCT  
 GGTACCAAAC TGGAACTGAA ATAA   
GCGGCC GCTGGATCCG AACAA 
  AAGCTGACTT CAGAAGAAGA CCTAAACTCA CATCACCATC ACCATCACTA 
 1051 ATCTAGAGGC CTGTGCTAAT GATCAGCTAG CTTGAGGCAT CAATAAAACG 
 1101 AAAGGCTCAG TCGAAAGACT GGGCCTTTCG TTTTATCTGT TGTTTGTCGG 
 1151 TTAACGTCGA CTCACTTGTC GTCATCGTCC TTGTAGTCTT TTTTAGCAGA 
 1201 ATCTGCGGCT TTCGCATCAG CTTCCGGCTT TGCATCAGCC TTCGGCGCTG 
 1251 GTTTCACATC CAGCAGCTCT ACGTCAAACA CCAGGGTAGA ATTCGGTGGG 
 1301 ATCCCCGGAA CACCCGCTTT GCCGTAAGCC AGTTCTGGTG GAATAACCAG 
 1351 TTTGATCTTA CCGCCTTTCT TGATGTTCTT CAGACCTTCT GTCCAACCCG 
 1401 GGATAACACC GTCCAGACGG AAAGAAAGCG GTTCACCACG GGTGTAAGAG 
 1451 TTGTCGAACT CTTTACCGTC GATCAGCGTA CCTTTGTAGT TCACTACAAC 
 1501 AGTATCGCTG TCTTTCGGTG CTTCGCCTTT ACCGGCTTCT ACTACCTGAT 
 1551 AAACCAGACC AGTTGAAGAG GTTTTCACAC CTTTCTCTTT GGCAAATTTC 
 1601 TCGCGGTACT CTTTACCTTT TGCTTCGTTA TCAGCCGCGT CTTTTTCCAT 
 1651 CTTCGCCTGA GCAGAAGACT TCACGCGAGC TTCGAATGCT TGTAGAGTCT 
 1701 GTTCGATCTC TTGGTCGGAG AGTTTGCTCT TATCAGCAAA TGCATCCTGA 
 1751 ACACCAGCGA TCAGCTGATC TTTATCCAGT TTGATGCCCA GTTTTTCTTG 
 1801 TTCTTTTAGA GAGTTTTCCA TGTAACGACC CAGCGAGGCA CCCAGTGCAT 
 1851 AAGCTGATTT CTGATCGTCA TTTTTGAACG CTGCTTTGCT GTCAGCAGCT 
 1901 GTAGCAGGTT TTGCAGCTTC AGCAGCAAAA GTGATTGGTG CATGCAGGGC 
 1951 AACGGCCATT GTGGTCGCCA GCAGCGTTAC TTTAAACAGT GATTTCATCC 
 2001 ATATCTCCAG GATCGGGGCA TCTCACCCCA GGGTTAACTA TTATCAGAAG 
 2051 GGTACTATAA AGCGTTGTCG AACAAATCTA CATACAGACA CGCCCTATTA 
 2101 TCATCTATTT TCAGACTCTT TTTGTTTAAA TTAGTTTCGA TGACCGCGAA 
 2151 ATGAGTGCTG TCTCGGGCAG CAAAGTTAAG TAGAATCCGC GGCGACCATT 
 2201 CGACAAAAGA GGTGAAGTCG ACCTGGCGTA ATAGCGAAGA GGCCCGCACC 
 2251 GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT GGGACGCGCC 
 2301 CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA 
 2351 CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT 
 2401 TCCTTTCTCG CCACGTTCGC CGGCTTTCCC CGTCAAGCTC TAAATCGGGG 
 2451 GCTCCCTTTA GGGTTCCGAT TTAGTGCTTT ACGGCACCTC GACCCCAAAA 
 2501 AACTTGATTA GGGTGATGGT TCACGTAGTG GGCCATCGCC CTGATAGACG 
 2551 GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA GTGGACTCTT 
 2601 GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT TCTTTTGATT 
 2651 TATAAGGGAT TTTGCCGATT TCGGCCTATT GGTTAAAAAA TGAGCTGATT 
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 2701 TAACAAAAAT TTAACGCGAA TTTTAACAAA ATATTAACGC TTACAATTTA 
 2751 GGTGGCACTT TTCGGGGAAA TGTGCGCGGA ACCCCTATTT GTTTATTTTT 
 2801 CTAAATACAT TCAAATATGT ATCCGCTCAT GAGACAATAA CCCTGATAAA 
 2851 TGCTTCAATA ATATTGAAAA AGGAAGAGTA TGAGTATTCA ACATTTCCGT 
 2901 GTCGCCCTTA TTCCCTTTTT TGCGGCATTT TGCCTTCCTG TTTTTGCTCA 
 2951 CCCAGAAACG CTGGTGAAAG TAAAAGATGC TGAAGATCAG TTGGGTGCAC 
 3001 GAGTGGGTTA CATCGAACTG GATCTCAACA GCGGTAAGAT CCTTGAGAGT 
 3051 TTTCGCCCCG AAGAACGTTT TCCAATGATG AGCACTTTTA AAGTTCTGCT 
 3101 ATGTGGCGCG GTATTATCCC GTATTGACGC CGGGCAAGAG CAACTCGGTC 
 3151 GCCGCATACA CTATTCTCAG AATGACTTGG TTGAGTACTC ACCAGTCACA 
 3201 GAAAAGCATC TTACGGATGG CATGACAGTA AGAGAATTAT GCAGTGCTGC 
 3251 CATAACCATG AGTGATAACA CTGCGGCCAA CTTACTTCTG ACAACGATCG 
 3301 GAGGACCGAA GGAGCTAACC GCTTTTTTGC ACAACATGGG GGATCATGTA 
 3351 ACTCGCCTTG ATCGTTGGGA ACCGGAGCTG AATGAAGCCA TACCAAACGA 
 3401 CGAGCGTGAC ACCACGATGC CTGTAGCAAT GGCAACAACG TTGCGCAAAC 
 3451 TATTAACTGG CGAACTACTT ACTCTAGCTT CCCGGCAACA ATTAATAGAC 
 3501 TGGATGGAGG CGGATAAAGT TGCAGGACCA CTTCTGCGCT CGGCCCTTCC 
 3551 GGCTGGCTGG TTTATTGCTG ATAAATCTGG AGCCGGTGAG CGTGGGTCTC 
 3601 GCGGTATCAT TGCAGCACTG GGGCCAGATG GTAAGCCCTC CCGTATCGTA 
 3651 GTTATCTACA CGACGGGGAG TCAGGCAACT ATGGATGAAC GAAATAGACA 
 3701 GATCGCTGAG ATAGGTGCCT CACTGATTAA GCATTGGTAA CTGTCAGACC 
 3751 AAGTTTACTC ATATATACTT TAGATTGATT TAAAACTTCA TTTTTAATTT 
 3801 AAAAGGATCT AGGTGAAGAT CCTTTTTGAT AATCTCATGA CCAAAATCCC 
 3851 TTAACGTGAG TTTTCGTTCC ACTGAGCGTC AGACCCCGTA GAAAAGATCA 
 3901 AAGGATCTTC TTGAGATCCT TTTTTTCTGC GCGTAATCTG CTGCTTGCAA 
 3951 ACAAAAAAAC CACCGCTACC AGCGGTGGTT TGTTTGCCGG ATCAAGAGCT 
 4001 ACCAACTCTT TTTCCGAAGG TAACTGGCTT CAGCAGAGCG CAGATACCAA 
 4051 ATACTGTCCT TCTAGTGTAG CCGTAGTTAG GCCACCACTT CAAGAACTCT 
 4101 GTAGCACCGC CTACATACCT CGCTCTGCTA ATCCTGTTAC CAGTGGCTGC 
 4151 TGCCAGTGGC GATAAGTCGT GTCTTACCGG GTTGGACTCA AGACGATAGT 
 4201 TACCGGATAA GGCGCAGCGG TCGGGCTGAA CGGGGGGTTC GTGCACACAG 
 4251 CCCAGCTTGG AGCGAACGAC CTACACCGAA CTGAGATACC TACAGCGTGA 
 4301 GCTATGAGAA AGCGCCACGC TTCCCGAAGG GAGAAAGGCG GACAGGTATC 
 4351 CGGTAAGCGG CAGGGTCGGA ACAGGAGAGC GCACGAGGGA GCTTCCAGGG 
 4401 GGAAACGCCT GGTATCTTTA TAGTCCTGTC GGGTTTCGCC ACCTCTGACT 
 4451 TGAGCGTCGA TTTTTGTGAT GCTCGTCAGG GGGGCGGAGC CTATGGAAAA 
 4501 ACGCCAGCAA CGCGGCCTTT TTACGGTTCC TGGCCTTTTG CTGGCCTTTT 
 4551 GCTCACATGT TCTTTCCTGC GTTATCCCCT GATTCTGTGG ATAACCGTAT 
 4601 TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA ACGACCGAGC 
 4651 GCAGCGAGTC AGTGAGCGAG GAAGCGGAAG AGCGCCCAAT ACGCAAACCG 
 4701 CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGGTATC ACGAGGCCCT 
 4751 TTCGTCTTCA C 
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Section B: Chemicals, hardware and software 
Table	  B1:	  Reagents	  
Chemical	   Vendor	  	   	  1	  kbp	  DNA	  ladder	   New	  England	  BioLabs	  Inc.	  
AccI	  (XmiI)	  FastDigest	   Fermentas	  Acetic	  Acid	   Merck	  Agar-­‐agar	   Merck	  Agarose,	  low	  melting	  point	   Sigma	  Alkaline	  Phosphatase,	  Calf	  Intestinal,	  (CIP)	  	   New	  England	  BioLabs	  Inc.	  Ampicillin	   AppliChem	  
BamHI	  FastDigest	   Fermentas	  Bovine	  serum	  albumin	  (BSA,	  100x)	   New	  England	  BioLabs	  Inc.	  Buffer	  #3,	  10x	   New	  England	  BioLabs	  Inc.	  Buffer	  #3.1,	  10x	   New	  England	  BioLabs	  Inc.	  CelLytic™	  B	  10x	   Sigma	  Cholesterol	  BioChemica	   AppliChem	  cOmplete	  inhibitor	   Roche	  Coomassie	  Brilliant	  Blue	  G250	   Amersham	  Biosciences	  Crystallisation	  Plate,	  96	  MRC	   SWISSCI	  Cuvettes	   Sarstedt	  Dibasic	  sodium	  phosphate	  (Na2HPO4)	   G-­‐Biosciences	  Dithiothreitol	  (DTT)	   Bio-­‐Rad	  Laboratories	  DNA	  Loading	  Dye	  Solution	  (6x)	   Lonza	  DNase	  I	   AppliChem	  DNase	  I	   Invitrogen	  dNTP	  mix	   Fermentas	  DreamTaq	  buffer	   Fermentas	  DreamTaq	  DNA	  polymerase	   Fermentas	  Duck	  Crystal	  Clear	  Sealing	  Tape	   Henkel	  
E.	  coli	  ArcticExpress	  competent	  cells	   Agilent	  Technologies	  
E.	  coli	  BL21DE3	  cells	   	  
E.	  coli	  XL1-­‐Blue	  CuCl2	  cells	   Stratagene	  
EcorI	  FastDigest	   Fermentas	  EKMax™	  10x	  reaction	  buffer	   Invitrogen	  EnterokinaseMax™	  	   Invitrogen	  Eppendorf	  tubes,	  1.5	  ml	  and	  2	  ml	   Eppendorf	  Ethanol	  Absolut	   VWR	  Chemicals	  Ethylenediaminetetraacetic	  acid	  (EDTA)	   Fluka	  FastDigest	  10x	  buffer	   Fermentas	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FastDigest	  10x	  Green	  buffer	   Fermentas	  Gentamycin	   AppliChem	  Glycerol	   Prolabo	  HiTrap	  Chelating	  HP	   GE	  Healthcare	  Hydrogen-­‐Chloride	  (HCl)	   Merck	  Imidazole	   Sigma	  In-­‐Fusion®	  HD	  cloning	  kit	   ClonTech	  Isopropyl-­‐β-­‐D-­‐thiogalactopyranoside	   Sigma	  
KpnI	  FastDigest	   Fermentas	  L-­‐Arginine	  HCl	   AppliChem	  Ligase	  buffer,	  10x	   New	  England	  BioLabs	  Inc.	  Lysozyme	   Sigma	  MES	  SDS	  Running	  buffer,	  20x	   Invitrogen	  Milli-­‐Q	  H2O	  (MQ-­‐	  H2O)	   Millipore	  Mono	  Sodium	  phosphate	  (NaH2PO4)	   Fluka	  
NcoI	  FastDigest	   Fermentas	  NEBbuffer	   New	  England	  BioLabs	  Inc.	  Nickel(II)	  sulphate	  (NiSO4)	   Sigma	  
NotI	  FastDigest	   Fermentas	  NuPAGE	  Bis-­‐Tris	  4-­‐12%	  gel	  	   LifeTechnologies	  NuPAGE	  LDS	  Sample	  buffer	  	   Invitrogen	  NuPAGE	  loading	  buffer	  (4x)	   Invitrogen	  NuPAGE®	  LDS	  Sample	  Buffer	  (4X)	   Invitrogen	  Optifit	  Refill	  Tips	   Sartorius	  PCR	  Cuvette	   Eppendorf	  Peptone	  from	  casein	   Merck	  Petman	  pipettes	   Gilson	  pFKPEN	  vector	   Gift	  from	  Geir	  Åge	  Løset	  –	  University	  of	  Oslo	  Phenylmethanesulfonyl	  fluoride	   Fluka	  BioChemica	  Primers,	  PCR	   Eurofins	  Genomics	  pRSET	  B	  expression	  vector	  with	  LXRα	  LBD	   LifeTechnologies	  pRSET	  B	  expression	  vector	  with	  LXRβ	  LBD	   LifeTechnologies	  SeeBlue®	   Plus2	   standard,	   molecular	   weight	  marker	   Invitrogen	  SH	  10x	  buffer	   Sigma	  Sodium	  carbonate	  (Na2CO3)	   Sigma	  Sodium	  chloride	  (NaCl)	  	   Prolabo	  Sodium	  hydroxide	  (NaOH)	   Kebo	  Lab	  Sodium	  thiosulfate	  (Na2S2O3)	   Sigma	  SuperDex200	  10/300	  GL	   GE	  Healthcare	  T4	  DNA	  ligase	  buffer	   Fermentas	  Urea	   Merck	  Vivaspin®	  20	  Centrifugal	  concentrators	   Sartorious	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VWR®	  Syringe	  filter	   VWR	  
XhoI	  	   New	  England	  BioLabs	  Inc.	  Yeast	  Extract,	  granulated	  
β-­‐mercaptoethanol	   Merck	  Sigma	  	   	  	  
Table	  B2:	  Equipment	  
Crystallization	  kits	   Vendor	  JSCG+	  suite	  Morpheus	   Molecular	  Dimensions	  Molecular	  Dimensions	  
Kit	   Vendor	  PCR	  Purification	  Kit	  (250)	  	   QIAGEN	  QIAprep	  Spin	  Miniprep	  Kit	   QIAGEN	  QIAquick	  gel	  extraction	  kit	   QIAGEN	  SilverQuest™	  staining	  kit	   Invitrogen	  
Instruments	  and	  lab	  equipment	   Vendor	  ÄKTApurifier-­‐900	   GE	  Healthcare	  Avanti	  Centrifuge	  J-­‐26	  XP	   Beckman	  Coulter	  Bench	  pH	  meter,	  3510	   Jenway	  Benchtop	  UV	  M-­‐20	  Transilluminator	   UVP	  Biofuge	  Fresco,	  Heraeus	   Thermo	  Scientific	  BX41	  microscope	   Olympus	  Canon	  PowerShot	  A480	   Canon	  Capsulefuge	  PMC-­‐06	   Tomy	  Centrifuge	  5810	  R	   Eppendorf	  CP224s	  Analytical	  Balance	   Sartorius	  Dri-­‐BLOCK®	  DB-­‐2A	   Techne	  Electrophoresis	  power	  supply-­‐EPS	  601	   GE	  healthcare	  Eppendorf	  Thermomixer	  comfort	   Eppendorf	  IKA-­‐WERK	  VF2	  vortex	  mixer	   Janke	  &	  Kunkel	  Jet	  900W	   Whirlpool	  Kelvitron®	  t	   Heraeus	  instruments	  LKB	  Model:	  GPS	  200/400	   Pharmacia	  Mini	  Horizontal	  Submarine	  Unit	   Amersham	  MQ-­‐H2O,	  Direct	  Q	   Millipore	  Multitron	  Standard	   Infors	  HT	  NanoPhotometer	  	   IMPLEN	  Oryx4	  robot	  	   Douglas	  Instruments	  PCB	  Precision	  Balance	   Kern	  	  PhotoDoc-­‐It™	  60	  Imaging	  system	   UVP	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Spectrafuge™	  Mini	  Centrifuge	   Labnet	  International	  Inc.	  SSM1	  Miniorbital	  shaker	   Stuart	  SterREO	  Discovery	  V12	   Zeiss	  TC-­‐3000	  PCR	  Thermal	  Cycler	   Techne	  Thermomixer	  comfort	   Eppendorf	  Transilluminator	  2000	   Bio-­‐Rad	  Tuttnauer	  3870-­‐ML,	  autoclave	   Tuttnauer	  UltraRocker	  Rocking	  Platform	   Bio-­‐Rad	  Ultrasonic	  cleaner	   VWR	  Ultraspec	  III	  KKB	   Pharmacia	  Unichromat	  1500	   UniEquip	  Vacuubrand®	   VWR	  XCell	  SureLock™	  Mini	  Cell	  Electrophoresis	  system	   Invitrogen	  
	  
Table	  B3:	  Software	  
Software	   Vendor	  4Peaks	   Nucleobytes	  Inc.	  Clustal2W	   EMBL-­‐EBI	  DeltaPix	  LE	   DeltaPix	  Multilayered	  Fusion-­‐based	  Disorder	  Predictor	   Biomine	  Software	  NEBcutter	  V2.0	   New	  England	  BioLabs	  Inc.	  ProtParam,	  ExPASy	  	   Swiss	  Institute	  of	  Bioinformatics	  Translate	  tool,	  ExPASy	   Swiss	  Institute	  of	  Bioinformatics	  Unicorn	  5.11	   GE	  Healthcare	  WaspRun	  Screening	  	   Douglas	  Instruments	  
	  72	  
 
Section C: PCR mixtures and programs, and PCR primers 
 
 
PCR of LXR LBDs to generate genes with and without a C-terminal hexahistidine tag, with 15 bp 
overlap with pFKPEN 
 
 
 
 
 
PCR-primers for amplifying LXR LBD and generating hexahistidine tag and 15bp overlap with 
pFKPEN vector. Some of the primers are common for both genes. 
 
α With and without tag: Forward (generating overlap): 
 5’ – GCTCAGCCGGCCATGG CCCAAGAAGAAGAACAGGCA – 3’  
 
β With and without tag: Forward (generating overlap): 
 5’ – GCTCAGCCGGCCATGGCAGGTGAAGGTGAAGGCGTT – 3’  
 
α and β Without tag: Reverse (generating overlap): 
 5’ – TCGGATCCAGCGGCCGCTTATTCATGAACATCCCAAATTTC– 3’  
 
α With histidine tag: Forward (generating random) 
 5’ – CCAGGCTTTACACTTTATGCTCCAAGAAGAAGAACAGGC – 3’ @ 
 
β With histidine tag: Forward (generating random) 
 5’ – CCTATCTTTACAATTTATGCT CGGTGAAGGTGAAGGCGT – 3’  
 
α and β: With histidine tag: Reverse (generating his-tag) 
 5’ – ATTTGGGATGTTCATGAACATCACCACCACCACCACTAA – 3’  
 
α and β: With histidine tag: Second Reverse (generating overlap) 
 5’ – CATCACCACCACCACCACTAA GCGGCCGCTGGATCCGA – 3’  
 
 
 
PCR mixture for amplification 
 
PCR program for amplification of 
linear hEndo-FL 
 
5 µl 10 mM dNTP 95 °C 30 seconds  
1 µl 10 µM forward primer (Eurofins) 95 °C 15 seconds 
x 10 
 
x 20 
1 µl 10 µM reverse primer (Eurofins) 45-68 °C 60 seconds 
2  µl pRSET B with LXR LBD 68 °C 15-60 seconds 
5 µl 10x standard Taq reaction buffer 68 °C 5 minutes  
0.25 µl DreamTaq DNA polymerase     
39.75  µl MQ – H2O     
50 µl      
